Plongez dans la liste complète des épisodes de Beginner's Mind. Chaque épisode est catalogué accompagné de descriptions détaillées, ce qui facilite la recherche et l'exploration de sujets spécifiques. Suivez tous les épisodes de votre podcast préféré et ne manquez aucun contenu pertinent.
Rows per page:
50
1–50 of 185
Date
Titre
Durée
06 Feb 2022
#67: Kai Lamottke - Bringing Innovation to Life Science From China & Europe
01:20:29
Innovation needs collaboration on a global scale. Making things happen requires entrepreneurs who love science and work day and night to connect the best minds globally and support them to translate their science into products and businesses.
In this episode, I have a conversation with Kai Lamottke, CEO and Co-Founder of Bicoll.
Dr. Kai Lamottke is co-founder & CEO of Bicoll GmbH and Bicoll Biotechnology (Shanghai) Co. Ltd., the first German-Chinese biotechnology company. His expertise and knowledge in life science and innovation sectors in China and Europe are requested by corporates, SMEs, and organizations, like European Commission. The excessive network of business, academic and political contacts allowed him to achieve business governmental grants with a value of over 23 Mio. € up to now
The Bicoll Group is a privately-owned biopharmaceutical company which includes Bicoll GmbH headquartered near Munich in Planegg / Martinsried, Germany, and its wholly-owned subsidiary Bicoll Biotechnology (Shanghai) Co. Ltd.
In this episode, we talk about
From Science to Business
Bicoll’s Mission
Finding the Business Model
How to Establish Business Between Continents
Operating in a Pandemic World
I hope you enjoy the conversation the same way I did.
BIALTEC assists animal protein producers to improve productivity and profitability through precision nutrition, understanding their particular dietary needs, analyzing them through a bioinformatics platform that uses artificial intelligence, and supplying the next generation antibiotic-free additives that will facilitate performance to obtain the desired results.
In this episode, we talk about:
The Problems in the Food Industry
What Solutions are in Development?
Bialtec’s Mission
Why You Should Create a Startup and
Much More
I hope you enjoy the conversation the same way I did.
#69: Prof. Collin Ewald - Molecular Mechanisms of Healthy Ageing
01:29:46
Lately, investors and researchers have published more and more information on longevity research and development.
Investors like Sergey Young or Christian Angermayer started to bet significant capital on this topic.
What is going on in this field on the research side? What are potential applications to increase the Lifespan? And when will those innovations hit the market?
In this episode, I had a conversation in December 2021 with Prof. Collin Ewald, ETH Zürich, about his longevity research and the future impact on the pharma industry. In this episode, we talk about:
What is the role of the extracellular matrix during aging and longevity?
Where is currently the innovation for longevity drug discoveries done?
What aging research is going on?
The Swiss Society of Ageing and Longevity Research
And much more…
Who is the expert in the show?
Prof. Ewald is Head of the Extracellular Matrix Regeneration Laboratory, Department of Health Sciences and Technology.
Collin has a longstanding interest in the molecular biology of healthy aging and age-related pathologies.
He is the founder and currently the president of the Swiss Society for Aging Research (www.ssfar.ch). He is named under the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland. He has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences.
Timestamps: (00:00) Opening about the situation in Switzerland and Austria in December 2021 (05:40) Longevity, Ageing, and the Health Span (07:05) Collin Ewald – Development of Ageing Research since the 90s (10:45) What is Ageing? (16:45) What is the Possible Lifespan of Human Beings? From Stone Age to the Future (20:10) What Factors Changed in Society that helped increase the average Lifespan? (22:45) The Importance of Education on Healthy Aging (26:15) How Education and Research Evolved with the Internet (27:00) Research Focus of the Collin Ewald Lab (33:30) Doubling the Lifespan in lab trials – is it possible to translate the research into human applications? (35:40) How to Translate Research into Products with Spin Outs. (38:00) Spin Outs from the Collin Ewald Lab (47:24) The Role of Extracellular Matrix in Ageing (54:40) The Potential for Applications for Cancer Diagnostic rooted in the research of the Collin Ewald Lab (56:15) How Artificial Intelligence Helps in Research (59:45) The Challenges Longevity Drug Development Faces at the Clinical Stage (01:03:45) The Role of Food & Science in Longevity Research (01:07:45) The Swiss Society of Ageing Research & Health Policies (01:13:00) Development of Life Expectancy (01:17:20) Healthy Ageing and Social Security (01:20:25) Advice to Young People Who Want to Create Lasting Change (01:25:35) The Killer Experiment - How Failure Creates Success
#70: Bruno Montanari - How Venture Capital Supports Science And Innovation
01:39:48
Big corporations strive to bring new solutions to their customers to help them solve their most pressing problems.
To do so the corporation needs to be innovative. That's why companies like Apple, Google, Pfizer, and similar players want to cooperate with start-ups and scale-ups globally.
Such cooperations strive to collaborate with top startups, invest in them, and sometimes acquire them to have access to novel ideas. By innovating the big players stay competitive, secure growth, and also help keep their employees motivated and curious.
One of the best ways to foster innovation is creating Venture Capital funds. Venture funds collect capital to invest in high-risk early-stage innovative startups to help them grow.
In this episode, we talk about:
Why is Venture Capital important for Innovation in Life Science?
What is the Secret Sauce of Venture Capital?
Venture Capital Success Stories
What is the Current Situation of Venture Capital in Europe?
And much more
Who is the expert in the show?
Bruno Montanari is a Partner at Seroba. He has a background in venture capital and in investment banking, with a focus on the pharmaceutical, biotechnology, and medical device industries.
Bruno sits on the boards of STORM Therapeutics and Coave Therapeutics.
Timestamps: (00:00) Introduction (03:30) Start of the Conversation “How Venture Capital Supports Science & Innovation” (03:45) What is Venture Capital? (07:30) Why is Venture Capital Necessary? (08:35) How Capital Intensive is Drug Development in Life Science? (11:55) Why Do Research Organisation and Big Pharma Need Companies in Between the Value Chain? (17:15) How Much Capital is Needed to Bring a New Therapy to the Market? (19:10) Why do some Life Science Start-Ups Fail? (24:30) How Can Venture Capital Help to Build Europe Into a Startup Continent? (31:53) How Innovation Changes the World (32:40) The Entrepreneurship Mindset between Academia and Industry (36:45) The State of Venture Capital in Europe (39:00) Elements Needed to Develop the Life Science Industry in Europe (42:35) Why Do Life Science Companies in Europe get Listed on the NASDAQ? (49:00) The Advantages of Specialized Investors (50:50) Benefits for Family Offices and High Networth Individuals to Invest in a Venture Fund Rather than directly into early-stage startup companies (59:00) Seroba Life Sciences (01:00:40) Success Stories from the Venture Capital Life (01:06:15) What kind of Deals are VCs looking for? (01:09:15) The Importance of Gathering Information before Closing a Deal – on both sides of the negotiation table (01:14:10) How to Balance Pitching and Relationship Building (01:19:30) 2x/10x/100X – Why are these metrics important to VCs (01:23:30) Deal Closed and they lived happily ever after – How does life look like post-investment? (01:27:00) How VCs Support Their Portfolio Companies (01:31:35) Warren Buffett vs. Venture Capital – Why is an Exit Important to VCs? (01:39:00) How to Reach Out to Bruno Montanari and Seroba Life S
#71: Heike Schoen - How To Rescue Your Clinical Trial When at Risk to Fail
01:36:44
Did you know that almost 90% of all product ideas fail in clinical trials?
Surprising to me was that lack of efficacy doesn't seem to be the main reason why clinical trials fail in the first place. Other factors are at play, and most of them are manageable risks when the right team is at work.
In this episode:
Strategic considerations for setting up a clinical trial
Inhouse vs Outsourced Clinical Study Management
Why clinical trials fail
Steps to getting your clinical trial back on track
Future trends of clinical trials
Who is the expert in the show? Heike Schön, Lumis International GmbH with more than 25 years of experience in international clinical research and drug development.
Timestamps: (00:00) Intro (02:25) Who Is Heike Schön, Lumis International and Lumis Consulting? (04:20) Topics in the Episode (04:30) Kick-Off (05:00) Background to Lumis International and Heike Schön (10:20) When is the Right Time to Start with the Planning of a Clinical Trial? (12:10) The Role of a Sponsor of a Clinical Trial (14:30) Who is Responsible for the Clinical Trial as a Sponsor? (16:55) When Should a Company Start to Implement Clinical Trial Management in the Organisation? (18:30) Funding Requirements for Clinical Trials (20:00) The Reality of Inhouse and Outhouse Clinical Trial Management (22:15) What to Think About When Planning Oversight Management (25:00) Relationship and Culture Management in Clinical Trials (27:25) Budget and Ressource Requirement for Clinical Trials (28: 45) 3 Steps to a Successful Clinical Trial (30:40) The 3 Main Reasons Why Clinical Trials Fail (33:30) Considerations for Patient Enrollment as a Key Success Factor for Clinical Trials (37:30) … and when enrolment fails, what are the steps to rescue the trial? (42:45) Do Inhouse Studies Require Rescue? (44:30) How to Rescue a Clinical Trial (48:30) Root Cause Analysis as a Starting Point to Rescue a Trial (52:25) Preventive Measures to Avoid Failure Early on (53:30) How Important is Leadership in a Clinical Trial? (56:30) The 3 Main Reasons to Stop a Clinical Trial – The Point of no Return (59:00) How are the Cost Calculated for Rescue Study Management? (01:00:15) Planning of a Clinical Trial – A Key Aspect of a Successful Trial (01:02:15) How to Plan Realistic Timelines and Numbers (01:07:15) The Role of Feasibility Studies in Clinical Trials (01:09:30) How Clinical Trial Management Evolved in the last 30 years (01:11:15) Upcoming Trends in Clinical Trial Management (01:13:15) Decentralized Clinical Trials (01:15:00) Artificial Intelligence And Big Data in Clinical Trial Management (01:17:55) The Digital Twin (01:19:15) The Human Factor and Leadership in Clinical Trial Management (01:21:10) The Patient in Clinical Trials (01:22:55) Planning and its contribution to clinical trial s
#72: Stefan Sandström - How to do Business in Japan
01:06:41
Do you want to reach out to Japanese companies and universities? Then you should know what makes Japan special and different to have a smooth business experience.
Different Cultures – Different Rules and Different ways to success
Japan is the second biggest market for pharmaceuticals globally. The area is not only interesting for its sales potential; it is also a major R&D hub in Asia.
One of the best experts in Japanese business culture in the LSG2G Community is Stefan Sandström.
Stefan Sandström is a serial entrepreneur who lived his first life in Sweden and is now living his second life in Japan. Instead of entrepreneurship, he's set up a business development consultancy in Japan aiming at the biopharma industry. After 15 years in Japan and partnering with Mr. Kuboniwa (retired from Chugai, chairman of the management committee of JBA, Japan Bioindustry Association, chairman of GTB, Greater Tokyo Bio community, and an advisor for the Japan Government), we always help find the best solutions in increasing traction or finding the right partners.
We are talking about: ➡️ Japanese Martial Arts ➡️ How is daily life in Japan ➡️ Japanese Meeting Culture ➡️ The Role of Informal Meetings and ➡️ How to Negotiate Prices in Japan
Do you want to get in touch:
⏩ Stefan Sandström: https://www.linkedin.com/in/stefan-sandstr%C3%B6m-22279053/ ⏩ Manifestum AB: https://www.manifestum.com/iris-biotech-an-exemplary-performance-of-how-to-do-business-in-japan/
🕒 Timestamps: (00:00) Introduction (02:00) Kick-Off and Greetings to Yokohama (03:15) The Covid Situation in Japan January 2022 (05:13) Reasons to Move to Japan (06:20) Kendo and Japanese Martial Arts (08:12) Martial Arts and Business (12:07) What Makes the Japanese Business Culture So Unique? (18:55) Daily Life in Japan (27:30) What are the 3 most important things everybody needs to know before traveling to Japan? (30:50) How Important is it to build business relationships in Japan? (32:40) Business Background Stefan Sandström (35:53) What is the Right Way to Engage with Japanese Companies? – A Case Study (41:45) Japanese Meeting Culture – What are the differences between formal and informal meetings? (43:45) Mind not only what happens in meetings but also what doesn’t happen in meetings (45:15) What does it mean when in subsequent meetings, similar questions are asked? (48:17) How is it perceived to change meeting dates on short notice? (51:55) How to set up informal meetings in Japan (58:50) How to Negotiate the Price in Japan (01:01:00) What is the best first step in creating business relations with Japanese companies?
Do you want to know how to value a company and what Julia Roberts has to do with it? Then listen to Bharat Kanodia in this episode number 73.
Valuation is one of the most difficult exercises in the startup world. How can you put a price tag on a company that doesn’t exist yet? Get help from an expert:
Bharat Kanodia has valued over 2000 businesses and signed off on assets worth $2.6 trillion in value. He has appraised unique assets like the Golden Gate Bridge, Atlanta Airport, Uber, Airbnb, Yahoo!, Brooklyn Bridge, Mirage Casino LV, among many others. Bharat is the Founder of Veristrat, a company that helps startup founders and VCs by telling them what their companies are worth. He lives in the San Francisco Bay area with his family and enjoys sailing, golfing, skiing, and horseback riding.
In this episode number 73 we are talking about:
➡️ The History of Entrepreneurship in San Francisco ➡️ Failure Culture ➡️ Julia Roberts ➡️ NFTs ➡️ And much much more...
🕒 Timestamps: (00:00) Intro Bharat Kanodia (04:00) History of Entrepreneurship in San Francisco (07:08) Failure Culture on the West Coast (08:40) The Startup Reality – 9 out of 10 attempts fail (10:10) Veristrat – Corporate Valuations (11:30) The Nature of Valuations (15:31) How to Deal With Valuations in the Startup World? (20:00) Valuating Companies on a Pitch Deck Basis (26:50) Beeple’s Everydays NFT – How to Put a Price Tag on It (32:00) The Valuation of Cryptocurrencies (35:34) How to Put a Price Tag on Early Stage Drug Development Companies (40:00) When Should Founders Start to get Professional Support for evaluating the company and their products? (43:35) How to Put a Price Tag on Landmarks like the Eiffel Tower (45:10) Life Habits of Successful Entrepreneurs (47:00) Atomic Habits (49:15) How to Reach Out to Bharat Kanodia
#74: Mark Herschberg - Why Networking and Leadership are Important Skills for Deeptech Entrepreneurs
01:20:37
Do you want to know why networking and leadership are so important to be successful in business? And why everybody, including employees, needs to learn those skills?
Then this episode is for you.
Mark is the author of The Career Toolkit, Essential Skills for Success That No One Taught You. Educated at MIT, Mark has spent his career launching and fixing new ventures at startups, Fortune 500s, and academia. He’s developed new software languages, online marketplaces, new authentication systems, and tracked criminals and terrorists on the dark web. Mark helped create the Undergraduate Practice Opportunities Program, MIT’s “Career Success Accelerator”, where he’s taught for twenty years. Mark also serves on the boards of non-profits Techie Youth and Plant a Million Corals.
➡️ Leadership ➡️ Entrepreneurship ➡️ What is Better: Alpha or Beta Leaders? ➡️ What Makes Exceptional Leaders like Elon Musk, Bill Gates or Steve Jobs? ➡️ And much much more
🕒 Timestamps: (00:00) Intro (02:00) How has life been on the East Coast in January 2022? (03:00) Travel Restriction and Mask Mandates in 2022 (05:30) Why Was it Necessary to Write “The Career Toolkit”? (07:02) The 10 Most Important Skills For Entrepreneurs (08:15) Why Are Those 10 Skills Not Taught at Universities? (11:00) What is Leadership? (13:15) Leadership and Influencers: What is the Difference in the skillset? (15:30) Is Leadership Learn- and Teachable? (17:45) Management and Leadership – What is the Difference? (20:32) Alpha Male and Beta Male – What is Better for Leadership in this Century? (23:30) Why Situational Leadership Matters (28:15) Character Traits of Exceptional Leaders Like Elon Musk, Steve Jobs, or Bill Gates (30:00) Leadership – Is it the Ceos' Job or also the duty of the Employees? (32:15) If you want to lead from the front, you must first learn to lead from behind (31:53) The Importance of Networking for Entrepreneurship (38:36) The Role of Networking for Fundraising Entrepreneurs (44:15) The Secret of Building and Maintaining Relationships (48:15) The Power of Introductions in Networking (49:43) Do Introduction Substitute the Relationship Building Phase? (51:45) Why Real Life Still Matters in Relationship Building (56:00) What Can and Cannot be done via Zoom During the Relationship Building Phase (01:02:36) The US Startup Eco-System in 2022 (01:06:30) What is the best way to approach the startup ecosystem in the US as a startup? (01:11:15) What is the US Eco-System Looking for in Startups? (01:14:30) The Big Vision – Why it Matters and Why Not (01:16:30) What is the best way to engage with the US Eco-System (01:17:40) Professional Background of Mark Herschberg and How you Can Reach Out to Him
#75: Lisa Stöger - Creating Connections Between StartUps and International Stakeholders
01:10:11
Are you interested to expand your business into Asian Markets? Then this episode might be for you.
As Program Manager of the Global Incubator Network Austria (GIN), Lisa Stöger has successfully connected the Austrian startup ecosystem with the world's most innovative startup hubs for the last 4 years. With a focus on Asian markets, she supports Austrian startups in their internationalization and market entry and introduces them to relevant, international stakeholders. Since 2016, GIN, co-managed by AWS and FFG, has been the contact point for startups regarding expansion from Austria to Asia and vice versa. Over 300 startups have benefited from the customized GIN services and internationalization programs. With her interdisciplinary academic background in Politics and Economics in Vienna and York (UK), Lisa is passionate about identifying cooperation potentials between international organizations and public institutions and is eager to apply these to promote startups and boost innovation.
What are the topics we discuss in this episode?
We cover 7 different eco-systems in Europe and Asia
🕒 Timestamps: (00:00) Opening (02:18) What is GIN? (05:00) Connecting the Start-up Eco-Systems in Europe with Asia (07:05) How Did the Pandemic Change the Way People Are Doing Business in the Startup Eco-System (10:30) The Potential of the Digitalisation in Creating New Business Relationships (14:04) The Start-up Eco-System in Israel – Linking Europe with Asia (17:05) Go Global Out of the Israeli Eco-System (18:05) The Start-Up Hub in Tel Aviv (22:05) The Silicon Wadi in Israel (24:40) Availability of Venture Capital in Austria (27:00) The Availability of Venture Capital in Austria for Companies Raising Series A Rounds and Beyond (29:15) Mainland China (33:57) How to Overcome the Language Barrier in Business (38:15) Contracts – Is English Sufficient? (39:06) The Eco-System in Singapore (41:22) The Tax Rates in Singapore (42:00) Singapore – The Gateway to South-East Asia (40:30) Startups in Hong Kong (45:00) Should Startups Create Subsidiaries in foreign Eco-System to gain more credibility? (51:53) The Start-Up Eco-System in Japan (55:15) The Japanese Business Culture (56:34) South Korea and Startups (57:18) The Business Culture in South Korea (01:01:34) The Covid Strategy in South Korea (01:06:25) What is the best first step into Asian markets? (01:08:35) Why Should Startups consider an entry into Asian Markets?
#76: Rich Masters - How the Pandemic Changed the Conference Industry - Bio US 2022 in San Diego
00:59:57
How Did the Conference Industry Change in the last two years?
Philadelphia in 2019 was the last Bio I attended in person. In March 2020, the world shut down to respond to the novel viral threat. Since then, all conferences have been digital.
What effect did this have on the conference Industry – especially the Bio US? Listen to Rich Masters, Chief Public Affairs and Marketing Officer of Bio.
As EVP for Public Affairs, Rich Masters leads integrated communications, branding, and marketing strategy for the organization, including overseeing the policy communications that support the advocacy goals across each of BIO’s sections.
What are the topics we discuss in this episode?
What are Bio and the Bio US 2022?
How Did the Conference Industry Respond to the Lockdowns?
🕒 Timestamps: (00:00) Intro (01:36) Who is Rich Masters (02:54) What is Bio? (03:30) Opening (04:30) How is The Situation in the United States with the Pandemic These Days? (05:40) How did the Pharma Industry Respond to the Global Viral Threat? (06:00) How did BIO Help Solve the Biggest Healthcare Challenge in the last 2 years? (08:33) What Is Biotechnology Innovation Organisation (BIO)? It is not only the Bio US. (12:10) How is the Availability of Capital for Biotechnology Product Development in the United States? (14:20) What Are The Bio Business Solutions and how does it help SMEs? (15:43) Is a BIO Membership for US Companies Only, Or is it Open for European and Asian Companies? (17:40) Entrepreneurship in the United States for Bio Product Development (18:24) Where are the Bio Hotspots in the US? (19:15) The Different Sides of BIO (20:15) Big Trends in Bio in 2022 (26:20) What A Convention Model Looks Like in a Post Pandemic World (31:35) Taking the Best of Two Worlds - New On-Demand Service – All Panel Discussions, Presentations, and Speeches in One Digital Space (33:35) Bio Impact in Omaha, Nebraska (36:05) Are Digital Conferences a Replacement for Real-Life Versions?
Add on Services at the Bio: (40:00) The Midway Experience in San Diego (41:00) I am Bio (42:05) Bio US Podcast – I am Bio (42:30) Good Day Bio (42:45) Bio.News
(44:25) Challenges for Conference Organizers that Came with March 2020 (41:30) How Bio Helps their Members to Overcome Challenges Ahead Especially the SMEs (55:35) Side Events at The Bio to Meet and Mingle with the Industry (58:25) Limitless - Rich Masters – See You on June 13-16 in San Diego to Celebrate the Work of Scientists
#77: Alexander Valtingojer - How to Invest in Digital Assets
01:50:43
What is going on in the world of digital assets in 2022? In May 2010, 10,000 BTC bought 2 Pizza.
Last year in November, the same amount had a value of 600 Million dollars. A lot has evolved since 2010 in the digital asset ecosystem.
That's why I asked Alexander Valtingojer, CEO of Coinpanion, to discuss the latest development in the crypto market. This episode was recorded in January 2022.
#78: Gerda Redl - The Future of Life Science Patents
01:29:11
Warren Buffett recommends buying companies with a great moat. Something that makes the company unique and protects the business from the competition. Patents are the best moats. Do you want to know why? Then listen to Gerda Redl.
Who is the speaker?
Dr. Gerda Redl is a patent attorney with more than 20 years of experience in the life sciences industry.
Her technical expertise is in biotechnology, biochemistry, and chemistry, including protein engineering, biologicals, small molecules, biomarkers, antibodies, alternative scaffolds, and libraries.
Before founding REDL Life Science Patent Attorneys, she held senior management positions in biotech, mid-size, and big pharma companies. She graduated as a biochemist and received her Ph.D. in microbiology from the Technical University of Vienna.
#79: Jonathan Sporn - How Psychedelic Drugs Help Ease the Mental Health Burden in Society
01:55:37
These days many sources are highlighting the shocking scale of the global mental health crisis and how this affects approx—a staggering one billion people worldwide - over one-seventh of the global population.
“Unfortunately, as harrowing and monstrous this number is”, the investor Christian Angermayer wrote in a blog post, “it is my belief this is a gross UNDER-estimate.”
Ultimately, the number of people needing mental health support is arguably all 100% of the world's population.
I invited Dr. Jonathan Sporn, CEO of Gilgamesh Pharmaceutical, to gain more insights into the unmet medical need in mental health and the promising novel psychedelic drug development sector
Jonathan Sporn MD is a Board Certified Psychiatrist, assistant professor at Columbia University, and CEO of Gilgamesh Pharmaceuticals, based in NYC, which is developing novel psychedelic-related or inspired medicines to treat mental illness.
Topics we discuss in this episode:
➡️ Global Mental Health Situation ➡️ The History of Psychedelic Drug Development ➡️ Investors in this promising area ➡️ The Background Story to the foundation of Gilgamesh Pharmaceutical and ➡️ And the Different Ingredients Needed to Structure a Novel Game-Changing Drug Development Company
🕒 Timestamps: (00:00) Introduction to Topic, Speaker, and Company (04:00) Life in New York in 2022 (07:15) The Global Mental Health Pandemic (10:39) Mass Shootings in the United States as a result of the Mental health Situation (14:05) Why is it Necessary to Develop Novel Drugs to Fight Mental Health Issues in Society (19:00) The History of Drug Development for Mental Health Patients (24:00) How Effective Are Psychedelic Drugs to Tackle Mental Health Questions? (25:05) Psychedelic Drugs in Pop Culture (26:40) What Inspired Jonathan Sporn to Dedicate His Professional Life to Advance R&D in Psychedelic Drugs (29:30) Psychedelic Drugs Help to Observe Own Behaviour (32:30) Root Causes of Mood Disorders like Maniac Depression, Bipolar Disorder (34:05) Psychedelic Drugs Enhance Neuroplasticity (36:50) From Basic Research to Drug Development in the Pharma Industry (40:10) Mental Health R&D at J&J (43:40) S-Ketamine vs. K-Ketamine – Difference and Similarities (46:35) Early-Stage Research in Big Pharma (49:00) Big Pharma and Small Biotechs (51:50) The decision to Start A New Company (57:00) Foundation of Perception Neuroscience – From Early Stage Research to Clinical Phase 2 to Exit (59:05) Atai Life Science – Continuing Development of the Compounds against Depression Supporting links: (01:00:00) Reasons for Becoming a Serial Entrepreneur After a Successful Exit Deal (01:06:00) Drug Development is Simple – Given an Experienced Drug Development Team (01:08:00) What is the unique approach of Gilgamesh Pharmaceutical? (01:10:15) Target Product Profile of Psychedelic Drugs (01:20:30) Gilgamesh Pharmaceuticals Mission and Vision (01:23:20) Patents in Psychedelic Drug Development (01:24:45) Business Model of Gilgamesh Pharmaceutical (01:29:00) Artificial Intelligence in Psychedelic Drug Development (01:33:14) Investing in the Psychedelic Drug Development Industry (01:37:22) Life Science VCs in the Psychedelic Drug Development Industry (01:39:00) Christian Angermayer, Peter Thiel, Mike Novogratz – Investors in Psychedelic Drug Development
#80: Alexander Belcredi and Lorenzo Corsini - How to Create An Overnight Success As An Entrepreneur
01:34:23
It is the 80th episode on my podcast channel. In 2020 I wanted to try how podcasts can bring value to my life science business community.
One of the first speakers on the podcast was Alexander Belcredi, Phagomed. He and Co-CEO Lorenzo Corsini started their Company in 2015 and developed Alternatives to Antibiotics.; which was also the title of Episode #9 - Alternatives to Antibiotics.
In April 2020, Alexander and Lorenzo were fundraising for their Company. Two years later, they signed an acquisition deal with the german Company BioNTech.
After the acquisition, I sometimes heard on the market that Alexander and Lorenzo's success story came a bit unexpected.
That's why I asked Alexander and Lorenzo to come back to the show to highlight how entrepreneurs create unexpected results in business.
Topics we discuss in this episode:
➡️ The Decision-Making Process to Start a Company ➡️ How to Build Processes, Structures, and Teams ➡️ The Reality of Fundraising ➡️ The 5 Key Learnings of First-Time Founders ➡️ And much, much more...
#81: Astrid Woollard and Christian Niedermüller - The Future of Investments in Digital Assets
01:26:32
What is happening in all things digital assets, cryptocurrencies, NFTs, and alike? The market crashed. Is it all over now?
Investing with experts is always the best idea when investing in new areas. This episode was recorded in February 2022, and I am happy that I had the chance to speak with two experts in digital assets from Austria:
Astrid is the CIO of Smape Capital. Their slogan is: We invest beyond mission-driven tokenized economies. She is also working as an independent consultant in digitalization, digital business models, blockchain technology applications, and IP strategy
Christian Niedermüller has been 15+ years in banking/traditional finance in very challenging roles, but finally went full time into the DLT/Blockchain and digital asset universe after being 6+ years massively involved anyway.
🕛 Timestamps (00:00) Kick Off (01:07) What is Smape Capital? (04:15) The History of Digital Assets (05:05) Who is Satoshi Nakamoto (07:07) Next Generation Token (09:53) Use Cases for NFTs (12:40) What Is DAO? (14:10) Astrid Woollard’s and Christian Niedermüller’s First Steps Into the Crypto Market (21:13) The Driving Forces Behind the Digital Asset Revolution (25:10) The Bitcoin Pizza Day (26:11) The Tokenized Economy (28:02) Use Cases for the Token Economy (33:10) Useability of Tokens for Investments in Equity, Real Estate, and other Asset Classes (37:00) Unbanking the Banked, and Banking the Unbanked (40:11) Digital Assets and Inflation. (42:55) The Remittance Network – An Opportunity for Digital Assets? (46:50) Money Laundering and the Blockchain (51:27) Digital Assets in the Metaverse – Why, What, And How (54:42) NFTs in the Metaverse (56:08) How NFTs Will Change the Gaming Industry (59:00) The Availability of Capital for Digital Asset Projects (01:01:51) New Funds in the Digital Asset Eco-System (01:06:01) Why Should Family Offices and High Networth Individuals invest in Funds Rather Than Bitcoin (01:12:42) The Future of Investing in Digital Assets
#82: Irene Fialka - Inspiring Stories from 20 Years of Bringing Academic Innovation Into Business
01:22:14
Happy Birthday, Inits. Today 20 years ago – July 27, 2002 – Inits – Vienna’s most important high Tech Incubation Program was created.
In this episode, I am talking with Irene Fialka, CEO of Inits. In 20 years, Inits has supported over 300 high-tech #startups with the necessary tools for a successful and sustainable market entry.
Dr. Irene Fialka is CEO of INiTS, Vienna’s University Business Incubator (UBI), supporting entrepreneurs with R&D-based business ideas serving all academic institutions in Vienna. She has a genetics/molecular biology background and has worked with deep-tech startups since 2004.
Under her leadership, INiTS was awarded three times by UBI Globalas, one of the TOP ranked UBIs in the world. INiTS’ startups have proven to be extremely successful in raising funds (12 x the average UBI-supported startup according to UBI Global) and finding strategic partners. She worked with the founders of, e.g., Apeptico, Blue Danube Robotics, Lexogen, Lithoz, Marinomed, mySugr, and many more. Marinomed is the first of over 300 companies that went public in 2019 (IPO on the Vienna Stock exchange).
In collaboration with partners such as Boehringer Ingelheim, Pfizer, and Uniqa, Dr. Fialka and her team launched the HealthHubVienna (healthhubvienna.com) in 2018, an acceleration program for international health startups to drive innovation and change in the healthcare industry in Europe. In this episode, we are talking about:
Success Story of Inits from 2002 to 2022
Development of the Startup Eco-System in Europe
3 Major Developments of Inits in the last 20 years
I wish the team of Inits all the best for their birthday celebration. Keep up your great work – it has a huge positive impact on the startup ecosystem in Europe
🕛 Timestamps (00:00) Kick Off (03:00) Birthday Wishes (04:00) When Did Inits Start? (05:30) From 2002 to 2022 – How Did the Eco-System in Vienna Evolve? (07:40) Early Days of Life Science in Austria – Intercell in 1997, Alexander von Gabain, Werner Lanthaler, Max Birnstiel (08:25) What was Inits Starting Point in 2002? (09:20) Tech Transfer in Austria Early 2000 – The Days of the “Ausseninsitut” (12:32) Business Models of Academic StartUps and Their Challenges – from 2002 to 2022 (15:20) Impressive KPIs of Inits (19:00) Companies are About Making Revenues (21:16) Inits For Academic Startups in 2022 (26:35) Public Funding in Austria (27:32) How the Campus in St. Marx Developed since 2006 – Vienna Bio Center, Start-Up Labs, Inits. (29:45) INits Support in 2004 (31:00) Coaching, Mentoring, and Advising for Startups (32:30) The 3 Major Developments at INITS Since 2002 (38:20) INiTs StartUps In Africa (43:20) Challenges and Opportunities in the Global StartUp Eco-System (45:05) StartUp Success Stories from the Inits Universe – MySugr, Shpock, Zoho, Marinomed, Origimm, Lithos, Ecop (52:05) Consistency between Strategy and Action – Aligning Interests (55:05) 3 Avoidable Mistakes in Startups (58:52) Patience and Endurance as Ingredients For Success (01:00:05) Digital Health – Health Hub Vienna (01:01:50) Inits Vision for the Coming Two Decades (01:02:15) Diversity and Female Founders (01:03:25) Integrating Circular Economy Concepts & Sustainability (01:04:00
#83: Donna LaVoie - How to Tell Your Story in 15 Slides
01:08:21
What is the best methodology for presenting your Company to investors, industry partners, and public funding organizations?
Here is the answer:
In this episode, Donna LaVoie presents her famous “15-slides-methodology” in great detail.
Donna is a proven strategic communications leader in health and science innovation. She is a trusted advisor on strategic communications issues, especially around complex problems affecting multiple stakeholders. She brings a unique combination of public and investor relations expertise, including product launch experience.
LaVoieHealthScience was launched in 2001 after a corporate career with signature biotech companies leading strategic communications functions during tremendous growth, product and business launches, and international geographic expansion.
As an acknowledged leader in health science communications with public and investor platforms, LaVoieHealthScience is recognized as a top 30 independent healthcare agency in the US. The agency has received more than 35 awards for its client work. It is recognized by INC.5000 Hall of Fame – Fastest Growing Private Companies, Boston Business Journal’s top Massachusetts PR firms, PharmaVOICE 100, and O’Dwyers.
We are talking about: ↪️ Why 15 slides are sufficient in corporate presentations ↪️ Why you should have an Agenda slide ↪️ Why an Appendix is important ↪️ What is Better? Detail or Simplicity? ↪️ The interplay of Problem and Solution ↪️ Why the Team slide matters ↪️ Why you need to adapt the presentation to your audience ↪️ And much, much more
🕛 Timestamps: (00:00) Intro (00:45) Donna LaVoie and LaVoieHealthSciences (02:35) Content of the Episode (03:00) Review of #bio2022 in San Diego (04:04) The 15 Slides Presentation Methodology (08:42) Why is the 15 Slides Methodology Relevant for Experienced Presenters? (12:15) Why are you here – What is your ask? (14:00) Why are conventions important? (16:05) Should Presenters consider the different cultural backgrounds when preparing for presentations? (16:51) The Importance of Colours (19:33) Storytelling, Simplicity, Novelty, and Clarity – The Ingredients of Successful Pitch Decks (24:00) Industry Dilemma (24:30) What’s Your Story? – 15 Slides Topics Overview (27:45) Title Slide (31:15) Company Snapshot (32:12) The Agenda Why Creating Anticipation as a Hook Matters in Presentations .(33:00) Describing the Problem and the Solution – Why it Matters (37:15) The Market and Target Product Profile (40:00) Competitive Positioning (42:20) The Team (46:45) The Pipeline and Clinical Data (50:00) Regulatory Strategy (51:00) Manufacturing Strategy (52:35) Commercial Strategy (55:00) Financials (56:45) Summary of the Presentation (58:30) How Specific Should Deal terms be in a Pitch Presentation? (01:01:45) Ending Slide – Cultural and Diversity Considerations (01:03:00) How Much Time Should Executives Take to Prepare their Corporate Story for Fundraising? (01:05:00) How LaVoie Health Science Helps Life Science Entrepreneurs and Investors
#84: Samantha Dale Strasser - Pepper Bio, MIT, And the Eco-System in Boston
01:10:57
What is the best approach to starting a novel deep tech life science company?
In this episode, I am talking with Samatha Dale Strasser, CSO, and co-founder of Pepper Bio, about her academic career at the University of Cambridge and MIT and the process of starting Pepper Bio.
Backed by VC firm NFX, Pepper Bio uses proprietary lab methods and computational abilities to unlock a new level of sophistication in drug discovery. Called the "Google Maps for drug discovery" Pepper Bio helps partners find the safest, fastest route to new, effective drugs in clinical trials by analyzing transomics data. So far, the company has already identified applications of its technology for rare diseases in oncology, neurology, and inflammatory.
Samantha Dale Strasser, PhD, is CSO and co-founder of Pepper Bio. Samantha co-founded Pepper Bio based on foundational work she pioneered during her PhD studies at MIT. Her development of the first trans-omic machine learning platform revolutionizes how we discover drugs and treat disease. This approach has already identified and validated previously unseen insights in inflammatory diseases and undruggable cancers. She paved the way to Pepper’s first commercial partner, eager to apply this approach to central nervous system diseases.
We are talking about: ⭐The Eco-Systems in Boston ⭐ The Importance of Aligning Vision – Mission – Goals – Actions ⭐ Challenges in Drug Development ⭐ Fundraising strategies for the United States ⭐The Story Behind Pepper Bio ⭐ And Much, Much more
🕛 Timestamps: (00:00) Introduction Pepper Bio and Samantha Dale Strasser (02:30) Start of the recording (03:00) Heatwaves, Paintings, and the Sky Above Boston (05:00) Culture in Boston/Cambridge and Cambridge, UK – MIT and the University of Cambridge (16:08) Samantha's Motivation to Start Pepper Bio (19:20) The Startup Eco-System in Boston, Massachusetts (21:27) The 3 Critical Key Success Factors of the Deep Tech Eco-System in Boston (24:40) Starting Points for Global Founders to Connect to the Eco-System in and around Boston (26:40) Real Life and Digital Meetings – The Best of Two Worlds (29:55) Fundraising in the United States – 3 Key Success Factors (33:17) Relationship-building with Investors and Duration of Fundraising in 2022 (31:08) The 3 Do's and Don'ts When Fundraising with US-Based Investors (44:05) Vision Statement – Pepper Bio (47:10) The Story Behind Pepper Bio's Foundation (51:12) Challenges in Drug Development to Improve Success Rates (55:49) Novel Solutions for Making Sense of Scientific Data (01:00:15) Pepper Bio's Team (01:03:30) The Importance of Aligning Vision – Goals – Actions (01:05:00) Hiring Strategy (01:05:30) Fundraising at Pepper Bio in 2022 (01:09:10) What is the Best First Step Towards Entrepreneurship?
#85: Emily Mitchell - What You Need to Know About Decentralized Clinical Trials
01:03:58
What are decentralized clinical trials?
What are the benefits of decentralized clinical trials?
Why are decentralized clinical trials the way of the future?
Emily Mitchell, Executive Director of ICON’s DCT team, discusses the benefits of these trials and what needs to be considered to ensure these benefits are realized.
Emily Mitchell has over 15 years of experience working in the CRO industry in Data Management, Project Management, and Clinical Operations. During her tenure at ICON, Emily partnered with an actigraphy vendor to run a pilot study with employees on the wear compliance and comparison of a medical grade activity tracker to a commercial grade version.
Before the pandemic, Emily helped set up and support the first fully decentralized trial at ICON. She has continued to present at various conferences around the best practices for decentralized studies, ensuring minimized patient and site burden while optimizing data capture. Emily is an active member of the Society of Clinical Data Management (SCDM) and has presented about decentralized trials at numerous conferences.
ICON is the only CRO to offer all services (without the need to contract third-party services or technology) and deliver end-to-end integrated decentralized clinical trial solutions.
ICON supported the delivery of the first decentralized clinical trial that has had positive published results in a medical journal – Nature Medicine
We are talking about
⭐ Decentralized clinical trials ⭐How they benefit patients ⭐The impact on budgeting ⭐Successful deployment of clinical trials an ⭐ Much, much more
🕛 Timestamps: (00:00) Intro (03:30) Kick off with Summer Weather (06:30) What are Decentralized Clinical Trials (DCT) (07:30) Benefits of DCT (08:45) Real-Life Example for a DCT from ICON Plc (11:48) What was the Motivation to Develop the DCT Model before the Pandemic? (14:30) Logistics in Clinical Trials (16:20) Managing DCT (17:45) Patient Response to DCT (18:35) Benefits of DCT in Increasing Diversity in Patients Population (22:30) More Diversity in Patient Population Equals More Valuable Data (26:00) The Role of Social Media in Patient Recruitment (27:22) Data Management in Decentralized Clinical Trials (29:25) Improvement in Data Collection With AI/ML, Tablets, And Wearables (31:07) DCT and associated cost (34:08) Which Indications are suitable for DCT? (37:30) How do decentralized clinical trials impact the duration of a trial? (40:15) How long does the planning phase in a DCT model take? (43:30) ICON’s Partnership Model (47:13) The Demographics of Social Media as a Recruitment Tool for Clinical Trials (50:10) Patient Experience in DCT (52:57) How to Keep Patients Motivated Through a DCT (56:00) Data Collection by Patients (57:40) Long-term follow-ups in the DCT Model (01:00:55) Patient Empowerment in Decentralized Cli
#86: Tobias Silberzahn - What is the State of Health & Wellbeing in Europe
01:25:27
In this episode, Tobias Silberzahn, McKinsey talks about biohacking 101 – habits that make a difference, digital health eco-system, and much more…
Tobias Silberzahn is a trained biochemist and immunologist and works as a Partner in McKinsey's Berlin office, where he is a member of the Healthcare and Innovation Practice. His work focuses on healthcare innovation, health tech business-building, and digital transformation.
Tobias leads the global Health Tech Network, a community of 1500+ health tech CEOs/Founders, where he hosts the quarterly Health Tech CEO Roundtable. As part of his work, Tobias also hosts the MedTech R&D Industry Roundtable and publishes the "eHealth Monitor Germany," an annual book about the digitization of the German health system.
Within McKinsey, Tobias leads the Health & Wellbeing program for employees, focused on sleep, nutrition, stress management, and fitness, that was recently awarded the Brandon Hall HCM Excellence Award in Gold.
McKinsey is a global management consulting firm committed to helping organizations accelerate sustainable and inclusive growth. McKinsey works with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. It combines bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for this generation and the next
Youtube(Links to articles discussed in the podcast are in the description to the Youtube Video)
We were talking about: ⭐ The European Health Care System ⭐ Biohacking 101 ⭐ The Healthtech Startup Eco System ⭐Small Habits – Big Changes ⭐ The 4 Pillars of Health and Wellbeing
🕛 Timestamps: (00:00) Introduction (05:30) The Situation of Mental Health, Health & Well-Being in Europe (10:10) The Role of Sleep For Health & Wellbeing (14:00) Mobility & Movement (18:43) Why Nutrition Matters (23:24) Healthcare and Cancer (29:46) Digital Tools for Managing Micro Habits (36:30) How Important are Digital Health Solutions for the Future Healthcare System – a Journey through State of the Art System (43:40) How Can Digital Tools Increase the Level of Health Literacy in Society? (49:30) How to Bring Health Education to all People –Solutions by McKinsey (58:54) How to Measure the Benefits of Happiness at Companies (01:02:38) The Cost of health deficits for the European Society (01:08:30) The Role Different Stakeholders Play to Improve the Healthcare System (01:16:30) Tobias Silberzahn’s Global Healthtech Network – A Community of 1,500+ Healthtech CEOs and Founders (01:20:30) The Future of Healthcare is Full Of Opportunities (01:21:35) The Role of Precision Medicine
#87: Tuvik Beker - How to Start a Life Science Company in Israel and Raise Capital in Silicon Valley
01:46:21
Fundraising in Israel and the United States – In this episode, I have a conversation with Tuvik Beker, CEO of Pangea Biomed, who has started, developed, and exited companies in the United States and Israel. Now he is developing Pangea Biomed to start the next revolution in precision oncology.
Tuvik Beker is a seasoned entrepreneur, an experienced executive, and a strong technical leader who spent the last twenty years building, scaling, and leading companies in the healthcare, financial, and aerospace domains.
Founded in 2018, Pangea Biomed is an Israeli biotech startup redefining cancer care. The company developed ENLIGHT – the world's most advanced multi-cancer, multi-therapy response predictor. By combining machine learning and deep RNA analysis, the company is mapping tumor molecular signatures to dynamically and adaptively personalize cancer care for a healthier world.
⭐In this episode, we talk about: The Startup Ecosystem in Israel Fundraising in the United States from 2000 to 2022 3 Success Secrets to Fundraising in the US Precision Oncology The Enlight Technology
🎤 Quotes: (11:58) “Nothing is Impossible" (31:05) “The Abundance of Capital is one important factor. Another one is, how the area around Stanford University welcomes immigration and foreign innovation." (35:33) “Many US Investors invest only in US companies” (40:26) “"If you want to succeed in fundraising, you need to have a wide funnel. You need to start talking to many, many venture capitalists to close a round." (44:21) “Be mentally ready to have 100 meetings or more to get the initial cheque.” (50:30) "The most important thing to bear in mind is building honest relationships with venture capitalists." (01:14:06) “Pangeas approach focuses on harnessing these expression abnormalities in order to attack cancer cells and spare normal healthy cells.”
🕛 Timestamps: (00:00) Opening (05:32) The Origin of Pangea Biomed (07:45) The Startup Ecosystem in Israel (10:16) Conversation Culture in Israeli Schools (12:05) IDF: “Nothing is Impossible” (13:55) Compulsory Military Service Contributes to the Success of the Startup Eco-System (19:03) Founding a Start Up in Israel (23:15) The Big StartUp Hubs in Israel (25:16) StartUp Life in Tel Aviv (28:00) StartUp Life in Palo Alto & Stanford (30:52) The Role of Silicon Valley in Entrepreneurship and Venture Capital (33:52) Fundraising in the United States from 2000 to 2022 (40:00) The 3 Success Secrets to Fundraising in the United States (56:00) Search Strategies During Fundraising in 2022 – signal.nfx.com (01:01:00) Recommendations when pitching US Investors (01:07:52) Pangea’s Solution in Precision Oncology (01:15:44) The Enlight Technology (01:20:30) How Pangea Helps to Find the Right Patient Population for Clinical Trials in Oncology (01:25:00) Pangea’s Collaboration Network (01:34:00) Enlight – Matchmaking between Patient and the right drugs (01:36:00) Pangea’s Business Model (01:40:00) Pangea’s Development Team (01:42:20) What is the next development step? (01:44:58) Advice to first-time founders
#88: Jia En Chin, Shirley Lu, Thijs Spoor: New Opportunities for Biotechs in China
01:17:53
What are the opportunities for Biotechs in the Chinese Market? Get answers to this question in this podcast with the BFC Group.
⭐We are talking about The BFC Group The Capital Market Landscape in China Deal Structuring in China Clinical Strategies for China Why Affordability and Accessibility of new drugs matter in China
⭐About BFC Group: BFC Group is a China-based investment banking firm with a focus on healthcare M&A, licensing, and financing. We work with leading healthcare companies in the US, Europe, and Asia. With first-hand operational experience in both the US and China, we have a deep understanding of the challenges our clients face when establishing or expanding their companies’ presence outside of their home market.
🎤 Quotes: (26:04) “China is now the second largest pharma market in the world, Japan being third” (31:11) “Many of our clients are still in Clinical Phase I, when they come to China” (33:29) “The China Market really rewards innovation in antibiotic research.” (48:30) “China takes care to make therapeutics accessible and affordable for the population” (51:24) “China's growing middle class wants to improve their quality of life.” (59:45) “Finding the right partner for a Go-To-China-Strategy is key to success. Otherwise, it can become very costly and might damage the asset.” (01:00:38) "... you want a personal connection, you want to educate and not sell..." (01:16:30) “In Q1/2022 18 new drugs were approved in China, 12 of them came from The West.”
🕛 Timestamps: (00:00) Introductions (13:00) BFC Group Introduction to the Chinese Market (15:45) Capital Market Landscape in China (18:30) China Investment and Financing Trend (21:43) Licensing Deal Trends in China (25:00) Opportunities for Biotechs in China (25:45) The biggest Pharma Markets and Innovators (30:00) Deal-Focus of Chinese Pharma Companies (32:00) The Therapeutic Focus in China in 2022 (33:41) Antibiotics Research in China (36:40) The Major Player in Infectious Diseases and Cancer on the Chinese Market (38:00) Market Potential in China for Chronic Diseases (39:55) The KBP Business Case (40:48) Patent Strategies for the Chinese Market (44:24) Important Points for Preparing a Market Entry in China (48:00) Price Dynamics and Reimbursement in China (49:30) Why Affordability and Accessibility Matters in China (50:30) The Necessary Data Packages for Market Entry in China (53:00) Clinical Strategies for Market Entry in China (56:30) Is a multi-center approach across several markets feasible in later-stage clinical trials? (01:01:30) Similarities and Differences in Culture, Communication (01:08:15) The Right approach for a Go-To-China Strategy (01:13:22) The Availability of Capital on Private and Public Markets for Foreign Companies
Where are the Big Life Science Hubs in the United States?
Here is an in-depth overview of Life Science In Georgia with many essential Key Facts and exciting stories from the beautiful state. My guest in this episode is E Jane Caraway, Director of Life Science at the Georgia Department of Economic Development.
⭐We are talking about
Life Science, Vineyards, Vampires and Zombies
Boehringer Ingelheim's Facilities in Atlanta
How Life Science Companies Help Communities
Science in Georgia
Starting a Life Science Company in Georgia as an Immigrant Entrepreneur
And much, much more
⭐About Georgia The state of Georgia is a dynamic hub for life sciences with more than 2,000 organizations. We have the resources to assist you in getting ideas researched, tested, commercialized, produced, and delivered quickly to most anywhere in the world. New and existing companies have access to a highly educated workforce, renowned research institutions, cutting-edge technological resources, and access to the global marketplace via a robust infrastructure. Georgia’s pro-business climate, combined with a culture of collaboration and innovation, has fostered growth across all sectors of life sciences.
⭐ EPISODE Links: E Jane Caraway: EJane Caraway, a passionate advocate for company success and community growth, has been with the Georgia Department of Economic Development for 13years. Since 2017 she has served as the Director of Life Sciences, and recently worked on projects with companies like Boehringer Ingelheim, Boston Scientific and IC Biomedical, just to name a few. Youtube
🎤 Quotes: (09:41) “Georgia has the second largest film industry in the world, after Canada and before Hollywood” (18:51) “The Soccer World Championship 2026 will be in the United States” (22:41) “Facebook has worked with local partnerships and entrepreneurs to build their own solar fields to supply energy to their facilities in Georgia” (28:41) "Georgia had a 150% growth in the Life Science Industry in 2021"
🕛 Timestamps: (00:00) Intro (03:00) Recap of the #bio2022 in San Diego (05:35) Background EJane Caraway and Life Sciences in Georgia (08:00) What do Life Science, Canyons, Vineyards, Vampires, She-Hulk, King of Queens, and Zombies have in common? (10:00) The Film Industry in Georgia (15:30) Sports in Georgia – Baseball, Soccer, Football, Golf, Pickleball (21:30) Georgia’s Leading Industries – Coca Cola, Delta Airlines, NCR, Facebook, Boehringer Ingelheim, HomeDepot, Aflac, UPS (23:45) Boehringer Ingelheim in Atlanta, Georgia and Vienna, Austria (28:55) Life Science in Georgia has seen a 150% Growth Rate in 2022 (33:00) The Positive Impact Life Science Companies Make in the Community – The Takeda Story (36:12) The Boston Scientific, AMRI and Gulf Stream – Ebola Story (41:21) Science in Georgia (44:30) Starting a Company in Georgia as an Immigrant Entrepreneur – How is the Workforce, Labspace, and Funding Situation in Georgia? (51:30) The Georgia Department of Economic Development is a One Stop Shop for Life Science Entrepreneurs (53:12) Success Stories from Life Science Companies in Georgia (57:14) Why should life science entrepreneurs start their businesses in Georgia? (59:25) Support the State of Georgia offers to entrepreneurs (01:02:39) Are you interested in starting your business in Georgia? Here is how!
#90: Brian Feroldi - Why Does the Stock Market go up?
01:08:52
Do you understand the dynamics of the stock market? Here is an episode with Brian Feroldi, Writer at the Motley Fool, on his new book “Why the stock market goes up?”
We are talking about ⭐ The Global Problem With Financial Literacy ⭐ Why Did Brian Feroldi Write a Book About Investing for Beginners? ⭐ Why Does the Market Crash from Time to Time? ⭐ Cost Averaging and Index Investing – A Powerful Tool for People who don’t have time to diligently follow the market ⭐ What was Brian’s Biggest Investment Mistake?
A basic understanding of the stock market is mandatory for every deep tech entrepreneur, business angel, and venture capitalist. A stock market is a place where companies can get more liquidity for scaling their business and provides an exit for early investors.
Brian Feroldi describes the mechanics of the stock market in his latest book: Why does the stock market go up? I enjoyed his unique way of explaining complex economic situations in easy-to-understand layman’s terms.
Brian Feroldi is a financial educator, YouTuber, and author. Since college, he has been intensely interested in money, personal finance, and investing.
📖 Quotes: (05:31) "A lack of financial literacy is a global phenomenon" (14:50) "...it took me about 18 months to write it. ... I think we needed a book that explains in plain English what the stock market is - for beginners." (16:11) "If you look back on stock market history - it is very clear: Every ten years ... or so ... things go to hell!" (33:00) "Only Business Profits drive the Stock Market in any given direction" (43:53) "Investing in an Index Fund is totally fine for 99% of investors because they have no interest in reading SEC filings or doing research." (01:08:00) "Think Long-Term"
⏰ Timestamps: (00:00) Introduction (01:52) Why Deep tech Entrepreneurs Need a Basic Understanding of the Stock Market. (04:00) Brian Feroldi's studio (05:17) The Problem With Financial Literacy (06:35) How Brian got Into Investing? (08:00) The Motley Fool (10:05) Why Did Brian Feroldi Write a Book About Investing for Beginners? (15:00) Reflecting on the Tech Market Correction in 2022 and Other Stock Market Crashes (19:19) The 2000 and 2008 Crash Experience (23:20) Why Does the Market Crash from Time to Time? (27:50) Crowd Mentality, Market Timing, and Contrarian Investing (32:55) The 3 Major Forces That Drive the Stock Market Up (36:55) Why Should People Invest When Fear, Uncertainty, And Doubt are on the Market? (39:32) What were your biggest questions when you started investing? (43:25) Warren Buffetts S&P500 ETF Strategy for People who don't have time for market research (45:23) Cost Averaging and Index Investing – A Powerful Tool for People who don't have time to diligently follow the Market (48:00) What is Compounding? (51:11) What is the Magnitude of Stock Market Fluctuations (55:05) Brian Feroldi's on Cathie Wood's Ark Innovation Fund (01:00:00) What was Brian's Biggest Investment Mistake? (01:04:00) Brian's Preferred Investment Style – Warren Buffett, Ray Dalio, or Cathie Wood?
#91: Marco Schmidt - AI in Drug Discovery and Drug Development: What You Need to Know
02:09:35
What is the Role of Artificial Intelligence in Drug Development and Drug Discovery?
⭐ In this episode, we talk about:
Deep Mind’s Alphafold
Investing in Life Science companies
The State of AI in Drug Development and Drug Discovery
How does GDPR limit the development of AI in Drug Discovery
The Human Genome and AI
Today’s speaker is Marco Schmidt, CSO of Biotx.ai Marco had an exceptional academic career. He won the best PhD of the year award in Chemistry in his home country Germany and then went on to do a Post-Doc at the University of Cambridge.
📖 Quotes: (24:45) “Eroom's law is the observation that drug discovery is becoming slower and more expensive over time” (56:05) “We need more data” (58:13) “Biobanks provide the infrastructure that we really need in the future” (01:16:39) “Prediction Models of Type 2 Diabetes Have 99% Accuracy” (01:17:50) “There is no longevity gene. There are shortevity genes.” (01:53:45) “We are living in fantastic times”
⏰ Timestamps: (00:00) Kick Off and Intro (06:15) Deep Mind’s Alphafold (07:06) Background to Marco Schmidt and Biotx.ai (12:00) Business Model in AI for Drug Development – from Service Provider to Developer (13:15) Basic Definition of Drug Discovery and Drug Development for the Listeners of the Episode (17:20) For Retail Investors who have an eye on investing in public drug development companies: What is a Ligand? (20:09) Why is Drug Discovery Expensive and Lengthy? (23:30) Success and Failure Rate in Drug Development (24:30) What is erooms Law? (27:25) What is the right place for innovation? Startups or Big Corporations? (30:00) The Value Chain in the Pharma Industry – From Research to Marketed Products. (34:00) Investing in Life Science Companies (50:15) Why is Artificial Intelligence an Attractive Area? Speaker and Company (55:00) The State of AI in Drug Development and Drug Discovery – What is Science and What is Still Fiction. (58:00) Accessibility of Data – Is this the bottleneck in Artificial Intelligence Based Drug Discovery? (01:10:00) What would change in Drug Development if scientists could access healthy population data? (01:12:30) Prediction Models for Cancer, Alzheimer, and other diseases (01:16:00) Understanding the progression of diseases and the role lifestyle plays in AI (01:19:00) How does GDPR limit the development of AI in Drug Discovery (01:24:00) Data Curation in AI (01:28:45) Is Capital a Limiting Factor? (01:34:26) The Human Genome and AI (01:40:00) Is it possible to simulate the entire drug development process from lab to market? (01:46:00) Service Offerings of biotx.ai (01:51:30) How can AI help select the right patients? (01:59:00) Synthetic clinical trials (02:01:00) The Role of Excel in Machine Learning
#92: Sebastian Mallaby - The Power Law - A Brief History of Venture Capital
00:54:38
How did Venture Capital evolve? When did it start? Get the answers right here in the book The Power Law by Sebastian Mallaby.
⭐ In this episode, we talk about: • Storytelling Methods and a Writers Work Process • What is Venture Capital – From the Writers Perspective • How Did Silicon Valley Evolve into the Center of the Innovation World? • The 3 Most Crucial Moments in the Development of Venture Capital • The Future of the European Tech Eco-System • And much, much more
📖 Memorable Quotes: (09:39) “In a Content Creators Economy where a lot of people spend a lot of time creating, it is worthwhile to spend 5 years writing a book” (12:46) “Do Venture Capitalists create innovation, or do they just show up for it?” (18:51) “Europe is fundamentally full of great engineers. It is a great market. Why wouldn’t it rival the United States if it got the right Venture Capital to take the risk.” (23:10) “The European culture is not as risk-friendly as the US. But it’s changing fast.” (27:45) “Genentech was the beginning of staged investments.”
⏰ Timestamps: (00:00) Speaker and Book Intro (02.25) Storytelling Methods and a Writer's Work Process (08:00) Development of the Methodology – From Nelson Mandela to Venture Capital (10:33) What is Venture Capital – From the Writer's Perspective (16:00) How Did Silicon Valley Evolve into the Center of the Innovation World? (19:39) Why Cover the Majority of the Stories about the US and Asia and very few stories about Europe? (27:41) The 3 Most Crucial Moments in the Development of Venture Capital (29:45) How Sequoia got into the hot tub with Atari (32:00) Softbank – Everybody Needs a 100 Million (39:00) Alibaba (43:45) The Future of Venture Capital (47:15) The Future of the European Tech Eco-System
⭐ Please support this podcast by checking out our partners: https://linktr.ee/lsg2g
Sebastian Mallaby is the Paul A. Volcker senior fellow for international economics at the Council on Foreign Relations (CFR). An experienced journalist and public speaker, Mallaby contributes to a variety of publications, including Foreign Affairs, the Atlantic, the Washington Post, and the Financial Times, where he spent two years as a contributing editor. He is the author of five books, most recently The Power Law: Venture Capital and the Making of the New Future.
#93: Thomas Schubert - The Role of Biophysics in Drug Development and Drug Discovery: What you Need to Know
01:46:04
What is the Role of Biophysics in Drug Development and Drug Discovery?
In this episode, I speak with Dr. Thomas Schubert, CEO of 2bind, a provider of biophysical outsourcing solutions for the pharmaceutical. Dr. Schubert discusses the role of biophysics in drug development and the importance of outsourcing in the pharmaceutical industry.
⭐ In this episode, we talk about: The Role of Biophysics in Drug Development The Role of Biophysics in Antibody Research Success Stories in Biophysics The Development of the Life Science Industry in Europe from the Biophysicist's Perspective Future Trends in Drug Discovery and Drug Development
Dr. Thomas Schubert received his Ph.D. in Biochemistry in 2012 from the University of Regensburg. Dr. Schubert joined 2bind in 2012 and was called for the CEO position in 2013. Dr. Schubert received the degree Betriebswirt (business economist) in 2014.
📖 Memorable Quotes: (04:30) “At 2bind, we are active with Webinars to educate people.” (08:15) “Biophysics is using physical measurement and interpretation to understand Biology" (24:40) “Many different changes in the environment of drug discovery occurred, and all of them pushed Biophysics.” (52:30) “Always employ people that are better than you” (01:29:27) “Biophysics will play a big role in Drug Discovery in 10 years”
⏰ Timestamps: (00:00) Intro (02:00) Recap Bio Europe in Leipzig and Bio International in San Diego after the Pandemic Break (04:15) Integrating Social Media into Business Strategies (07:30) The Role of Biophysics in Drug Development (11:00) Background Thomas Schubert and 2bind (20:00) How has the Role of Biophysics in Drug Development evolved over the last 10 years (26:30) The Role of Biophysics in Antibody Research & Development (29:30) Biophysics and ADCs (33:00) 2bind’s position in the pharmaceutical value chain (38:30) How to combine scientific and development mindsets in the industry (43:30) Competition and Expertise in the Biophysics World (46:15) Technologies used in biophysical research projects (52:19) Challenges for Entrepreneurs Running a Deep Tech Service Business (56:30) Success Story #1: Lead Identification with 2bind (58:30) Success Story #2: Formulation Study with an HIV Vaccine Candidate (01:03:00) The Big Challenges for Pharma in this Century – Antibiotics, HIV, Cancer (01:10:00) The Development of the Life Science Industry in Europe (01:17:00) Outsourcing – when is it the best solution for companies? (01:24:00) Future Trends in Drug Discovery and Drug Development from the Biophysicist’s Perspective (01:36:00) Epigenetics, AI, and Chess (01:43:00) How to Connect with Thomas Schubert
#94: Adrian Brodesser - Virtual Reality: A Game-Changer for the Future
01:37:08
Which Role do Wearables like Virtual Reality Devices play in the Future of Diagnostics?
In this episode, I am excited to talk with Adrian Brodesser, CEO of Somareality, to explore the latest technological developments and their impact on society.
Adrian will be joining us to discuss the use of VR in diagnosing neurological diseases and how these devices are revolutionizing the way we approach healthcare. From Alzheimer's to Parkinson's, virtual reality is providing doctors with new tools to understand and treat these complex conditions.
So join us as we delve into the world of VR and healthcare with Adrian Brodesser and learn how this technology is changing the game for the diagnosis and treatment of neurological diseases.
⭐ We discuss topics like: •How to find product market fit for VR •Core Business of Somareality •VR Use Cases in Healthcare and Sports •Use Cases for VR-based Diagnostics •Challenges of Entrepreneurship
📖 Memorable Quotes (10:00) "Entrepreneurship is really hard." (48:10) "With Eyetracking, we can measure if the person is overwhelmed with parts of the process." (50:30) "The AI helps people to understand where they are struggling and which steps they should take from here on." (01:00:09) "A lot of great insights into the early-stage dedication of diseases can be derived from eye-tracking." (01:10:30) "Technology-based Diagnostics will be vastly available in the future" (01:32:00) "3 pieces of Advice for New Entrepreneurs"
📚 Book Mentions: (17:30) Jimmy Soni The Founders
⏰ Timestamps (00:00) Kick Off (06:40) Entrepreneurship in 2022 (12:40) The Art of saying no (20:30) The Magic of Finding Product Market Fit (24:05) Selling – The Most Important Skill for Startups (28:34) How to Sell to the Healthcare Industry (32:15) Core Business of Somareality – Usecases for VR (41:00) How VR helps to understand the User Better (44:12) Commercial Potential of VR – Intuitive Surgical, Lufthansa and Somareality (52:15) Use Cases in Healthcare and Sports for Attention Tracking (56:00) Digital Diagnostics with VR (59:15) The Research Behind Eyetracking with VR for Diagnostics (01:02:23) Aware Virtual Reality Systems – The Future of VR (01:10:26) The Long-Term Future of VR-based Diagnostics (01:16:25) Near Future Use Cases for VR-based Diagnostics (01:19:00) Elevator Pitch for VR-based Diagnostics (01:22:35) Objective Pain Measurement with VR (01:29:00) Fundraising (01:30:50) Custom Solutions for the B2B Environment (01:31:00) 3 Points for Entrepreneurs who start a business
SP1: Merry Christmas 2022 to the Podcast Community
00:04:40
As the holiday season has started, I wanted to take a moment to wish you all a very Merry Christmas. I hope this time of year brings you joy, peace, and happiness.
Remember to stay positive and hopeful as we look ahead to the new year.
2023 is a new opportunity to set goals, make positive changes, and achieve our dreams.
I hope you can spend this holiday season with loved ones, surrounded by warmth and cheer.
May your Christmas be filled with love, laughter, and everything that brings you joy.
#95: Jimmy Soni - The Founders - The Story of Paypal and the Entrepreneurs who Shaped Silicon Valley
01:39:33
In this episode, I unlock the untold stories behind PayPal's meteoric rise and the entrepreneurs who made it possible.
The author Jimmy Soni explores the captivating story of PayPal and the entrepreneurs who helped shape Silicon Valley.
From Elon Musk to Peter Thiel and many others whose stories have never been told, hear about the scrappy online payments start-up that faced fierce competition and internal strife on its journey to becoming one of the world's foremost companies.
🗣️ We are talking about: • The Inspiration for writing this book • Dissecting Jimmy’s Writing Process • The Origin Story of the Paypal-Mafia • The Role of Chess and The Secret Code Hidden in the Book • Storytelling Lesson for Entrepreneurs • And much, much more
📖 Memorable quotes: (20:55) “I do my books while working full-time. All my books are morning and weekend exercises.” (24:46) “I interviewed almost 300 people for this book.” (35:45) One executive said: "Calling Paypal a Mafia is an insult to the Mafia. They are far more organized than we were back then." (51:04) “David Sacks said: … as easy as email” (56:50) “The most important question for business owners: Who in the team is obsessed with how the end-user thinks and uses the product?” (01:34:30) People forget that startups are stories.
⏰ Timestamps: (00:00) Intro from the Recording the Day after Thanksgiving 2022 (05:55) What inspired Jimmy Soni to write the Founders? (10:00) The Entrepreneurs who Shaped Silicon Valley (16:15) Peter Thiel: How to Learn the Right Lessons in Entrepreneurship (19:24) How long does it take to write a book like the Founders? (22:15) Writing Books as a Side Hustle to writing as a profession (23:00) Exploring the Challenges of Writing Biographies of Historical and Modern Figures (25:23) Uncovering the Truth: Strategies for Sorting Through Conflicting Narratives in Interviews (27:30) The Writing Scorecard: Number of Words per Day (28:40) Uncovering the Journey from Idea to Publication: A Look at Jimmy Soni's Writing Process (30:30) Max Levchin and Tetris (32:17) The Origin Story of the Term “Paypal-Mafia” (39:00) From Beaming Money to Venmo: 20 Years of Product Development (43:00) David Sacks Halts the Progress of Groundbreaking Beaming Technology and the Birth of Digital Payment Solutions (49:40) How Paypal Found Product Market Fit (53:42) The Switch challenges from finding a solution to focusing on scaling up the solution. (58:00) The Role Chess Plays in Jimmy Soni’s Book and Paypal’s History (01:02:27) The Secret Code Hidden in the Book: Crack the Code and Get a Signed Copy (01:03:00) The Bad Bishop Situation (01:06:00) Bitcoin, the Paypal Mafia, and the New World Currency Tagline (01:15:00) Elon Musk's challenges in finding the right decisions during his early twenties. (01:20:27) Discover Jimmy's book's three most inspiring moments as he personally selects them. (01:29:30) How important are social skills in building tech companies? (01:32:00) Some Words on the Importance of Storytelling for Entrepreneurs (01:35:00) Sketching a Future of Jimmy So
#96: Kurt Höller - This was 2022 - Year in Review Part I
00:35:33
Welcome to the year-in-review podcast for 2022!
As the year comes to a close, I am excited to reflect on the successes and learnings from the past 12 months and look ahead to what 2023 has in store.
I have an incredible lineup of speakers from 90 previous podcast episodes; the event was live-streamed before Christmas on LinkedIn, YouTube, Twitter, and Facebook, so listeners could tune in from anywhere.
To conclude the year and start into 2023, each speaker will be featured in their podcast episode.
As a starter, I am thrilled to have Kurt Höller from EIT Health joining. Kurt will share his most memorable moments from 2022, his biggest successes and learnings, and his expectations for 2023. We'll also be discussing EIT Health and getting an overview of the LSG2G community.
Kurt Höller is the Director of Business Creation at EIT Health, a leading healthcare initiative supporting over 750 startups and providing access to key industry players. He has a wealth of experience in healthcare, including founding and directing several companies, and a strong background in research, with a focus on health innovation.
We have a full schedule of speakers lined up, including Caroline E. Heil from The New Meat Company, Albert Missbichler, a business angel, Lina Toro and Mauricio Agudelo from Bialtec, Kimberly Cornfield from UCL, Collin Ewald from ETH Zurich, Guido Gualdoni from G.ST Antivirals, and Thomas Schubert from 2bind.
We'll be tackling questions such as: •What excited you the most in 2022? •What should change in 2023?
I hope you enjoy the episode from this exciting year-in-review event.
⏰ Timestamps: (00:00) Intro to Year in Review, Kurt Höller, And EIT Health (03:00) Chat GPT as a helper to find questions for the podcast recording (04:30) Kurt shares his personal highlights from 2022 (07:30) EIT Health in 2022 (08:30) Events after the pandemic – From EIT Health Summit to Bits and Pretzels (11:00) Bits & Pretzels – The European Woodstock for Startup Entrepreneurs (12:55) Bavaria, White Sausages and Beer Habits (14:30) Kurt’s New Role as Managing Director of InvestHealth (17:30) The Venture Capital Situation in Europe in 2022 (21:28) Healthtech Investment Trends in the Coming Years (23:30) Europe Becomes a Single Market for Health Apps (34:00) Estonia – Leader in Digital Adoption in Many Categories
#97: Caroline E. Heil - This was 2022 - A Year in Review - Part II
00:31:41
Welcome to the second part of "This was 2022 - A Year in Review," a special edition of the Beginner’s Mind Podcast as we close the year and look ahead to 2023. I'm your host Christian Soschner, and I'm excited to be joined by Caroline Heil, CEO of The New Meat Company.
Caroline is a seasoned investor passionate about revolutionizing the food industry sustainably and healthily. She has worked for EY as a lawyer. She has experience advising clients on corporate aspects of M&A transactions and VC investments, with a focus on the alternative protein and meat market, food security, and sustainability.
The New Meat Company is a purpose-driven impact investment company based in Berlin that invests in game-changing companies and founders disrupting the traditional meat industry with sustainable, nutritious, and tasty alternatives. They have a buy-and-build strategy, consolidating established pioneers and emerging game-changers in the alternative meat space and partnering with innovative individuals who prioritize animal welfare and reducing the ecological footprint of meat production.
In this episode, Caroline will share her insights on the key trends in the food industry, the importance of proper nutrition for long-term health, and her advice for startups and scaleups seeking investment. She'll also give us a preview of what to expect in 2023 and the ideal investment opportunity for The New Meat Company.
So sit back, relax, and get ready to learn from one of the top investors in the food industry as we close out the year and look ahead to the future.
We have a full schedule of speakers lined up, including Kurt Höller from EIT Health, Albert Missbichler, a business angel, Lina Toro and Mauricio Agudelo from Bialtec, Kimberly Cornfield from UCL, Collin Ewald from ETH Zurich, Guido Gualdoni from G.ST Antivirals, and Thomas Schubert from 2bind.
We'll be tackling questions such as: •What excited you the most in 2022? •What should change in 2023?
I hope you enjoy the episode from this exciting year-in-review event.
SP2: Happy New Year 2023 - Thank you for your support
00:02:27
Hey everyone, this is Christian Soschner from the Beginners Mind Podcast I just wanted to take a quick moment to say thank you for following the podcast channel in 2022. Your support and engagement mean the world to me, and I am truly grateful for each and every one of you.
As we head into the new year, I want to assure you that I will continue to bring you valuable content in health, healthcare, pharma, artificial intelligence, entrepreneurship, and investing. These topics are close to my heart, and I am dedicated to sharing the latest research, insights, and trends with you.
But it's not just about the content but the connection. I am committed to building a community of like-minded individuals who are passionate about these topics and are eager to learn and grow together.
So let's make the most of this new year. Let's decide today who we will become, what we will give, and how we will live. And let's do it with purpose, passion, and a desire to impact the world around us positively.
Thank you again for your support. I look forward to continuing to bring you valuable content and being a part of this amazing community in 2023 and beyond.
And before you leave for the new year's celebrations, please consider hitting the like button, leaving a comment, and following our channel. Your support helps me grow my podcast and allows me to reach more people who can benefit from my content. And if you have a moment, please consider leaving a 5-star review on Apple Podcasts and Spotify – it really helps me out. Thank you again and have a happy new year!
Welcome to the first days of 2023! As we bid farewell to the past year, I wanted to take a moment to appreciate all the amazing conversations on my podcast over the past 12 months. From global crises to personal triumphs and failures, 2022 has been a year like no other.
I covered various topics on the show, from venture capital to clinical development, psychedelics, virtual reality, and biophysics. In honor of these incredible episodes, I have decided to end the year with a compilation of the best moments from the previous 12 months.
It was difficult for me to choose just five standout conversations from the many I've had, so I enlisted the help of ChatGPT to generate five numbers between 60 and 97 randomly. These five episodes are the ones I've chosen to highlight.
But as we enter the new year, it’s also a time to look ahead and plan for what lies ahead. In the words of CS Lewis, "The future is something which everyone reaches at the rate of sixty minutes an hour, whatever he does, whoever he is." So grab your holiday cheer, join me as I reflect on the past year’s highlights, and look ahead to what’s in store in the new year. The clock is ticking, and the future is waiting. So, don't miss out and tune in to this YouTube video for all the exciting details!
#99: Albert Missbichler - This was 2022 - A Year in Review - Part 3
00:35:23
Welcome to the third part of "This was 2022 - A Year in Review," a special edition of the Beginner's Mind Podcast.
I'm your host Christian Soschner and I'm excited to be joined by Albert Missbichler, a business angel with over thirty years of experience in biochemistry and clinical diagnostics.
In this episode, we'll be discussing the highlights of 2022, the differences between scientific B2B and B2C, and the challenges of translating science into simple words.
We'll also be exploring the lifestyle habits and health literacy of Gen Z, as well as the crucial habits for longevity.
Finally, we'll be discussing the changes in the post-pandemic conference industry and the big trends to look out for in 2023 in diagnostics.
Stick around for all of this and more with Albert Missbichler on the Beginner's Mind Podcast.
⏰ Timestamps: (01:23) Prediction Caroline Heil for 2023 (02:06) Introduction Albert Missbichler and Fianostics (03:00) Highlights Albert Missbichler in 2022 – from B2B to B2C (04:40) The Biggest Differences between Scientific B2B and B2C (07:00) Challenges of Translating Science into Simple Words (11:30) Lifestyle Habits and Health Literacy of Gen Z (17:45) Crucial Habits for Longevity (21:15) Postpandemic Meeting Habits – What changes, what remains (25:20) Changes in the Post-Pandemic Conference Industry (28:00) Big Trends in 2023 in Diagnostics (32:00) Inoolab and Fluobolt
The Top 5 Most Downloaded Episodes: A Look Back at 100 Episodes of Success with Scientific Entrepreneurs and Investors
01:21:02
Celebrate with us as we reach our 100th podcast episode!
Join us as we look back on the past three years and revisit the 5 most downloaded episodes.
From exploring the use of blockchain technology in the energy sector, to gaining valuable insights into the daily life of a VC and learning how to succeed in the competitive world of drug development, this special episode has something for everyone.
Thank you for being a part of our journey and for supporting our mission to promote scientific entrepreneurs and shape a bright future for humanity. Don't miss out on this celebratory milestone episode!
SP 3: Is ChatGPT The Future of Content Creation or The End of It? The Truth Behind The Hype
00:20:54
Are we on the brink of a technological revolution that will render content creators obsolete?
Join us as we explore the rise of ChatGPT and its potential impact on the creative industry. From its capabilities as a natural language processing tool to its comparison to Bitcoin in the financial world, we'll discuss the pros and cons of this game-changing technology. Tune in to discover the truth behind the hype and what it means for content creators like you.
⏰ Timestamps: (00:00) What Novel Technology Means (03:30) What is ChatGPT? (04:50) What Does ChatGPT Mean for the Creative Industry - ChatGPT Usecases (06:45) How ChatGPT can help in the Brainstorming/ideation Phase (10:00) Utilizing the Research Phase with ChatGPT (12:15) How can ChatGPT Help with Producing a Piece of Content? (15:38) ChatGPT as a Team for Rewriting, Editing, and Repurposing Content to Make it Native to Different Platforms (18:00) Ethical and Legal Questions
#101: Lina Toro and Mauricio Agudelo - Unlocking the Secrets of Precision Nutrition and AI in the Animal Protein Industry: Insights from BIALTEC's Founders
00:30:05
Are you ready to discover the secrets of precision nutrition and AI in the animal protein industry?
Join us as we speak with the founders of BIALTEC, Mauricio Agudelo and Lina Maria Toro, to gain exclusive insights on the industry's challenges and opportunities.
From tackling logistics and inflation to understanding the future of animal nutrition, this episode is packed with game-changing information you won't want to miss.
Tune in now and get ready to be inspired by the innovation and vision of BIALTEC.
⏰ Timestamps: (00:00) Introduction Lina Toro and Mauricio Agudelo, Founders at Bialtec (05:54) Creating Microbiomes for Animals (09:13) Big Challenges in 2022 for Bialtec – Logistics and Inflation (11:38) How did Lina Toro, CFO of Bialtec, deal with the global environment (13:31) Perceived Inflation Rate in the Bialtec Eco-System (14:19) Energy Prices in South America in 2022 (16:40) Bialtec’s Activities in Europe (20:22) 3 Improvements for Founding a Company in Europe (25:28) Trends in the Animal Nutrition Industry in 2023
#102: Uncover the Hidden Strategies for Securing Funding and Achieving Impact in European Research
00:28:45
Are you ready to unlock the secrets of securing funding and achieving impact in the world of European research and innovation?
In this episode of our podcast, we explore the latest trends and developments in research and innovation with Kimberly Cornfield, Assistant Director (Project Development & Management) and Head of European Research and Innovation at University College London (UCL). UCL is one of the top-performing universities under the EU's Horizon 2020 program and has secured around €400 million over the last seven years to support its research and innovation activities.
Kimberly and her team connect scientists and businesses around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving impact objectives.
We'll discuss the current state of European research funding, the challenges and benefits of virtual meetings, and the future for research and innovation.
⏰ Timestamps: (00:00) Introduction Kimberly Cornfield, UCL, and Horizon Europe (05:12) Highlights UCL and Horizon Europe Grant Funding in 2022 (07:20) Advantages and Challenges – Virtual or Real Life Meetings? (09:00) Benefits of the Virtual World for UCL Research Projects (10:21) Horizon Europe (14:28) Future Trends in Research (17:28) The Rise of Social Sciences (19:28) The Relevance of Fairy Tales for Research (23:05) The Horizon Europe Work Programme for 2023 (26:00) Wishes for 2023
#103: The Future of Aging Research: Insights from the Founder of the Swiss Society for Aging Research, Dr. Collin Y. Ewald
00:36:57
Introducing "The Year in Review Recordings", a series where we reflect on the past year and look forward to the coming one. Hosted by Christian Soschner, this podcast brings you expert speakers from previous episodes and partners of the podcast to give you an in-depth analysis of the latest advancements in their fields and an outlook for the future. This is the 6th conversation in the series.
In this episode, we have Dr. Collin Y. Ewald, founder and president of the Swiss Society for Aging Research and head of the Extracellular Matrix Regeneration Laboratory at the Department of Health Sciences and Technology. Dr. Ewald has a longstanding interest in the molecular biology of healthy aging and age-related pathologies. He is a leading expert in the field and has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences. He is named among the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland.
We'll be discussing Dr. Ewald's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages. We'll also be discussing the Ewald Lab's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages.
This episode also includes topics such as Longevity Research and Horizon Europe, How to Bridge the Gap in Horizon Programs between scientific disciplines and different languages, The 9 Hallmarks of Ageing, Solving the Clinical Trial Challenges in Longevity Research, Food Supplements for Longevity in 2023, Collin Ewald’s Spin Out Company, The 10 Simple Rules to Start a Successful Spin-Off Company, 2023 in Longevity Research – Upcoming Trends.
Don't miss out on this episode of "The Year in Review Recordings," where we dive into the world of longevity research with Dr. Collin Y. Ewald and stay informed about the latest advancements in the field.
#104: Revolutionizing Respiratory Antivirals: The Science behind G.ST Antivirals
00:32:58
On this episode of "Year in Review Recording," we speak with Guido Gualdoni, Co-Founder, and CEO of G.ST Antivirals, a clinical-stage biotech company revolutionizing how we treat viral infections of the respiratory tract.
Guido shares the science behind G.ST Antivirals' innovative host cell-based strategy to develop broad-spectrum antivirals and how it completely eliminates viral reproduction without the risk of resistance development. He also delves into the public funding and startup ecosystem in Vienna, Austria, which has been instrumental in the company's success.
He also talks about the future plans for G.ST Antivirals and the deep scientific tech valley in Central Europe. This episode is a must-listen for anyone interested in the latest advancements in biotech and the companies leading the way in treating viral infections.
⏰ Timestamps: (00:00) Welcome to the Episode: Exploring the Public Funding and Eco-System in Vienna, Austria (02:35) Meet Guido Gualdoni, CEO of G.ST Antiviral (04:00) Discovering the StartUp Labs, Vienna Business Agency, AWS, FFG, Austrian Business Agency, LISA Vienna and their role in supporting startups (07:35) Exploring the Scientific Deep Tech Valley in Central Europe: Munich, Vienna, Zurich, Prague (10:15) G.ST Antiviral's 2022 Outlook (11:22) Uncovering the Innovative Technology Behind G.ST Antiviral (14:30) Guido's Biggest Takeaways from 2022 (16:15) Why Optimism Bias Can be a Challenge for Entrepreneurs (18:15) Comparing the Scientific and Entrepreneurial Mindsets (24:00) The Surprising Companies that Succeeded During Economic Downturns (25:00) Examining the Latest Trends in Antiinfectious Diseases (27:45) Charting the Growth of G.ST Antiviral in 2023
#105: Expert Insights on Biophysics and the Future of Drug Discovery: An Interview with Dr. Thomas Schubert of 2bind
00:34:07
Are you ready for the grand finale of our Year in Review Recording?
The final episode of 2022 is here, and it's one for the books! We've explored the cutting-edge innovations and technologies shaping the future of the biotech industry with some of the most brilliant minds in the field. From Kurt Höller of EIT Health, to Albert Missbichler from Fianostics, Caroline Heil from the new meat company, Mauricio Agudelo and Lina Toro from Bialtec, Kimberly Cornfield from the UCL, Collin Ewald from ETH Zurich, and Guido Gualdoni from G.ST Antiviral, we've had some truly enlightening conversations.
But we saved the best for last!
Get ready for an exclusive interview with Dr. Thomas Schubert, CEO of 2bind, a provider of biophysical outsourcing solutions that is revolutionizing the way we study molecular interactions and protein stability. Don't miss out on this one-of-a-kind episode.
Tune in now!
This cutting-edge biotech company is revolutionizing how we study molecular interactions and protein stability. They're doing it with a track record of over 1400 successfully completed tasks in research projects with over 350 customers in the last 11 years.
In this episode, you'll get an inside look at the driving force behind 2bind and the expert knowledge that sets them apart in the biophysics field. From breakthrough moments to industry trends, you'll gain a deeper understanding of the future of biotech and the role that companies like 2bind will play in shaping it.
But that's not all! You'll also hear from Dr. Schubert about the company's partnerships with leading device producers and how they navigate the digital world to stay ahead of the curve. Plus, you'll get insight into the supply chain challenges that 2bind faced in the last years and how they overcame them.
Don't miss out on this opportunity to learn from the best in the business! Tune in to our latest podcast episode and join the conversation on the future of biotech.
Trust us; this episode is a must-listen for anyone in the biotech industry or anyone passionate about innovation and the future of medicine. It's packed with valuable insights and information you won't miss.
⏰ Timestamps: 00:00) Introduction (02:00) Unveiling the mastermind behind 2bind, Dr. Thomas Schubert (04:05) Insider tips for starting your own biotech company (07:36) A glimpse into the future: 2022 for 2bind's CEO (10:40) Navigating the digital world: Pros and cons of technology in biotech (14:16) Overcoming obstacles: A look at 2bind's supply chain challenges (18:21) Game-changing developments in biophysics for 2022 (19:53) What's next for the industry? A preview of biophysics trends to come (23:19) Peeking into the crystal ball: 2bind's plans for 2023 (24:25) Mark your calendars: Upcoming conferences featuring 2bind in 2023 (30:49) Bold predictions for the biotech industry in 2023 (32:33) Addressing the challenges: How to improve drug discove
#106: Breaking Barriers: Jeevan Sunner's Journey as a Female VC
01:29:21
Are you curious about what it takes to be a female venture capitalist in 2023?
Join us as we sit down with Jeevan, a successful woman in the industry, to discuss the world of female entrepreneurship and venture capitalism. With her insights on the tech focus areas of 2023, the challenges of attracting women into the VC world, and the importance of warm referrals, Jeevan offers a unique perspective on the startup investment landscape. Get a glimpse into the life of a female VC as she shares her journey and valuable lessons learned. Tune in now to learn what it takes to become a venture capitalist in 2023 and expand your knowledge on the exciting world of startup investments.
📖 Memorable quotes: (49:33) “Linkedin Made Investors in Silicon Valley Accessible” (49:55) “Communication, Accessibility, Relationship building, and Information sharing make social media super powerful.” (55:40) “Take your time and do your due diligence on investors to understand whether their values are aligned with yours and whether you see that 10-15 years partnership happening.” (59:30) “We are flexible in the way we collaborate with founders. It can be a more passive approach, or for first-time founders more hands-on” (01:09:00) “When it comes to dilution, we rather have a smaller slice of a bigger pie, than a massive slice of a smaller pie”
⏰ Timestamps: (00:00) Unlocking the Secrets of Venture Capital: An Insider's View (03:15) Brave the Winter of England with Jeevan in December 2022 (05:44) The Journey to Becoming a Top Venture Capitalist in 2023 (11:00) Spotting the Next Big Tech Trend in 2023 (14:20) Empowering Female Entrepreneurs and VCs to Create Change (20:00) Breaking Barriers: What it Takes to Attract More Women in Tech VC (23:00) The Power of Warm Referrals and How VCs Evaluate a Pitch deck (26:00) Timing is Everything: When is the Right Moment to Approach a VC? (30:30) A Day in the Life of a Busy Venture Capitalist (39:30) Decoding Job Titles in Venture Funds: What They Really Mean (44:15) The Human Side of Investing: Why Relationships are Key (46:15) 2 Vital Lessons for Founders from a VC's Perspective (48:55) The Rise of Social Media in the Startup Investment World 2023 (50:35) Podpower: The Importance of Podcasts in Building Relationships in 2023 (52:25) Jeevan's Must-Listen Podcast List for Entrepreneurs and Investors (56:50) Expectations Beyond Returns: What VCs Look for in Founders (01:04:30) The Investors' Role in Board Functions and Aligning Interests (01:09:50) Finding the Perfect Match: Product/Market Fit (01:13:50) Jeevan's Most Exciting Deal: Behind the Scenes (01:16:25) The Art of Closing a Deal: A VC's Perspective (01:17:55) The Challenges of Closing a Deal and the Path to Success (01:20:45) Predicting the Future of VCs: 2023 and Beyond (01:25:00) The Final Word: Jeevan's Advice for Entrepreneurs and Investors
SP 4: Arnold Schwarzenegger's 6 Rules of Success: A Guide to Living Your Dreams
00:44:08
Uncover the Secrets of Success with Arnold Schwarzenegger - Mastering the 6 Rules.
In this episode, join us as we delve into the mind of one of the greatest action heroes and successful entrepreneurs of our time.
Arnold Schwarzenegger shares his personal experiences and lessons learned as he reveals the key elements of his famous "6 Rules for Success" speech. Get inspired and motivated as you discover the blueprint for achieving your goals and realizing your dreams.
⏰ Timestamps: (01:34) Rule #1: Have a Vision (13:12) Rule #2: Ignore the Naysayers (22:18) Rule #3: Work your A** Off (28:01) Rule #4: Don’t have a Plan B (33:38) Rule #5: Give Back (39:52) Rule #6: You Need Help
#107: Jack Scannell - Uncovering Drug Development Efficiency Secrets: The Science Behind Pharmaceutical Research
02:01:27
Do you ever wonder why it takes so long for new drugs to hit the market? Have you ever questioned the efficiency of the pharmaceutical industry?
Join me in this episode as we talk to Jack Scannell, a pharmaceutical industry expert, and discover the hidden efficiency secrets of drug development. In this episode, we delve into the critical factors that have shaped drug development over the last 60 years and analyze the industry's current state.
Throughout the podcast, Jack draws on his extensive industry knowledge and provides insights on the importance of decision quality, the role of AI in drug discovery, and the economics of the research model.
If you're looking to gain a better understanding of the pharmaceutical industry and its inner workings, join us in uncovering the efficiency secrets of drug development. Tune in to this episode.
(11:41) “Between 1950 and 2010, Drug Development saw a halving time: Every nine years, the number of drugs developed per billion dollars spent halved.” (24:58) “4 Reasons for the Decline of Drug Development Productivity: Better Than the Beatles Problem, Higher Regulatory Hurdles, Throw Money at it Problem, Misindustrialisation of Science (26:30) “Metformin is the Pharmaceutical Equivalent to the Beatles” (45:15) “In early drug discovery, predictive validity, the degree to which your model output correlates with human clinical utility is critically important” (01:19:31) “If the only tool you have to measure the height of the fruit is the rate at which you are picking fruit, and you notice that the rate of picking fruit is declining, you will always blame the low hanging fruit problem.” (01:34:15) “When capital is freely available, the average quality is going down”
⏰ Timestamps:
(00:00) Introduction: Uncovering Drug Development Efficiency Secrets (06:30) Background Jack Scannell: Pharma Journey (09:15) Finding erooM’s Law: Playful Experiment Leads to Discovery (12:00) Inversion of Output Efficiency: More Capital, Fewer Drugs (13:15) Best Key Figure for R&D Productivity? (20:24) Factors Behind R&D Productivity Decline - 1950 to 2010 (25:30) The Beatles Inform Drug Development (28:34) The Regulatory Problem (30:00) Throwing Money at the Problem & Misindustrialisation of Science (31:00) Turnaround in Drug Development Efficiency from 2010 (38:30) Speeding Up Early-Stage R&D (45:45) Technical & Managerial Components to Improve Speed (47:10) Improving Predictive Quality of Models - Alzheimer's Case Study (57:00) Interplay of Different Forces in Complex Problem Solving (01:02:30) Model Quality Matters the Most for High R&D Quality (01:12:45) Making Pharma Value Chain More Effective (01:18:00) Appropriate Success Measure for Drug R&D? (01:21:05) Role of AI in Drug Discovery Process (01:29:32) Limiting Factor of AI in Biology? (01:31:00) Availability of Capital a Limiting Factor in Drug Development? (01:39:00) Economics of Research Model - Common Goods Problem (01:47:00) Role of Public Funds to Validate R&D Model Quality (01:52:00) Truth Seeking Over Progression Seeking Behaviour: Prioritizing Scientific Integrity in Drug Deve
SP 5: Unleashing Your Creative Potential: Sol LeWitt's Timeless Advice to Eva Hesse
00:14:20
Are you struggling with your creative process?
Do you feel stuck in a rut or blocked by perfectionism? You're not alone. In this episode, I explore the remarkable letter from artist Sol LeWitt to Eva Hesse, which has inspired creatives for decades.
Not only creatives can get stuck and blocked. Also, entrepreneurs, scientists, and investors can have to face such situations in their lives.
Read by Benedict Cumberbatch for Letters Live at the Freemason's Hall in London, LeWitt's timeless advice urges us to stop overthinking and DO.
Embrace the process, let go of perfectionism, and believe in your ability to create.
Join me as I discover the wisdom of emptiness and how it can help you unleash your full potential. From conceptual art to minimalism, I delve into the fascinating lives of Sol LeWitt and Eva Hesse, two American artists who embarked on a supportive friendship that would inspire them both.
So sit back, relax, and let's listen to the words of Sol LeWitt as read by Benedict Cumberbatch. This episode is a must-listen for anyone looking to break free from creative blocks and unleash their full potential.
⏰ Timestamps (00:00) Unleashing Your Creative Potential: The Remarkable Letter from Sol LeWitt to Eva Hesse Read by Benedict Cumberbatch (01:15) Background Information to Sol LeWitt, Eva Hesse, and their Inspiring Correspondence (04:00) Sol LeWitt's Timeless Advice to Eva Hesse: Stop Overthinking and Just DO (06:25) Perfectionism Kills Creativity (08:57) Embrace the Process, Don’t Focus on the Outcome (10:09) Believe in your ability to create
#108: Alex Zhavoronkov - Revolutionizing Medicine: How AI Will Cure Aging
01:12:59
Are you ready to dive into the future of medicine and the revolutionary advancements being made with artificial intelligence? In this episode, I sit down with Alex Zhavoronkov, the founder and CEO of Insilico Medicine, a global company focused on the discovery of novel therapeutics utilizing cutting-edge technology in healthcare.
From longevity research to anti-aging treatments, Alex shares his expertise on the most impactful field of our time, discussing his work in protein target discovery and the design of small molecule drugs using generative AI.
But it doesn't stop there. Alex also shares insights into the development of aging clocks, biomarkers of aging, and precision medicine. Discover how generative AI is transforming the pharmaceutical industry, improving clinical trials, and providing a revolutionary new approach to drug discovery methods.
Don't miss out on this incredible opportunity to learn from one of the leading experts in AI and healthcare innovation. Tune in now and join us on this fascinating journey into the future of medicine.
📖 Memorable quotes: (10:50) “Insilico Medicine synthesized and tested the first AI generated drug in 2017.”
(23:09) “Generative AI in Drug Discovery and Drug Development has the potential to improve the probability of success by 50%”
(24:00) “Generating 11 preclinical candidates in 2.5 years - is a pretty cool number.”
(29:48) “We developed a clinical candidate in 18 months at a 3 million dollar cost with the help of AI. The traditional route takes 2 years at about 400 million expeonses.”
(01:08:48) “Generative AI will transform our lives beyond recognition in every way.”
⏰ Timestamps: (02:00) Introduction to Alex Zhavoronkov at World Government Summit 2023
(03:00) About World Government Summit 2023
(04:20) Alex's longevity research at Insilico Medicine
(08:20) Accelerating drug discovery with AI
(13:00) AI in synthetic biologic data
(15:00) Generative AI in reducing cost and increasing output
(23:30) Generative AI in increasing probability of success
(25:00) Why traditional drug R&D takes over 10 years and 2 billion 2010 dollars
(28:45) AI-driven drug discovery at Insilico Medicine
(30:30) Insilico Medicine's pipeline and case study
(38:09) Regulators' perception of AI in drug development
(45:26) Generative AI in clinical development
(49:15) Audience question on AI and microbiome research
(53:30) Operating a company between China, Middle East, and North America
MM 1: Alex Zhavoronkov - Transforming Drug Discovery Forever: How AI Is Revolutionizing Medicine and Changing Lives!
00:07:47
Welcome to our new series, Memorable Moments!
In this series, we bring you highlights from past episodes that contain some of the most memorable insights and important information that you won't want to miss.
In this episode, we explore the groundbreaking potential of AI in drug discovery and anti-aging research.
Listen in as we share clips from our interview with Alex Zhavoronkov, who is leading the charge in this revolutionary technology that cuts costs, increases success rates, and drastically shortens the time it takes to develop new therapies.
Join us as we share memorable moments and life-changing insights that will help you discover the incredible potential of the future of medicine. Don't miss out on this powerful and inspiring episode of our podcast - tune in now!
⏰ Timestamps 00:00 Intro 00:44 Alex Zhavoronkov Explains how his solution increases the probability of success, cuts costs and timelines in Drug Discovery and Development 07:20 Shout out to our new subscribers on Buzzsprout+
SP 6: Saving the World from Extinction: A Review of Andy Weir's 'Project Hail Mary
00:02:51
In this video, I review the science fiction novel "Project Hail Mary" by Andy Weir. As a fan of the genre, I was excited to dive into this action-packed and thought-provoking book that takes a critical look at some of the global issues we face today.
I discuss the strengths and shortcomings of the book, as well as its potential pleasures and delights for science fiction enthusiasts. Join me as I explore the captivating story of Ryland Grace, a science teacher who wakes up alone in a spacecraft and must use his knowledge and skills to save the earth from an alien threat.
Don't forget to leave a comment with your thoughts on the book and whether you would recommend it to others.
MM 2: The Shocking Truth Behind Declining Drug R&D Productivity with Dr. Jack Scannell
00:13:36
In today's episode, we uncover the hidden crisis in the pharmaceutical industry as we explore the alarming state of R&D productivity. Our guest, Dr. Jack Scannell, is a renowned scientist and entrepreneur with extensive experience in both the biotech and investment fields. He shares his valuable insights into the concept of Eroom's Law, which reveals the inverse relationship between input efficiency and output efficiency in drug research and development.
Listen in as we discuss the challenges of measuring R&D productivity and how financial return and number of drugs approved per unit input serve as key indicators of productivity. Dr. Scannell helps us understand the reasons behind the decline in R&D productivity since the 1950s and the factors that have contributed the most to this concerning trend.
Don't miss this enlightening conversation that exposes the harsh reality of pharmaceutical R&D productivity, and be sure to share your thoughts and opinions by leaving a review or engaging with us on social media. We'd love to hear from you!
Stay informed on the latest developments in pharmaceutical R&D productivity and other pressing global challenges by subscribing to our podcast. Your support helps us continue to bring you thought-provoking discussions and expert insights.
#109: Philipp Baaske's Journey: From Small Village to Biotech Entrepreneur
02:01:14
Join us in this episode as we talk to Philipp Baaske, CEO of Nanotemper, and explore the ins and outs of building a successful biotech startup. We cover topics such as bootstrapping, finding customers, developing effective leadership skills, and more. Gain valuable insights and advice from Philipp's experiences as a business angel and entrepreneur. Tune in to learn how to build and scale a successful biotech startup.
📖 Memorable quotes: (36:18) "First of all, I disagree with Steve Jobs, it's important to talk with customers about their problems, but it's really about the problem, not talking about a technical solution." (48:17) "If you don't fail, you do something wrong because if it always works, you don't do the risky thing; you just do the easiest thing." (01:10:20) "This is my advice on startups: sell. Sell a product before you have it because if the customer gives you money for it, you know that it's worth developing it." (01:12:39) "We never thought about failing. Failure was not in our mind." (01:19:31) “I strongly believe that every disease is treatable.”
⏰ Timestamps: (00:00) Introduction (02:30) The Impact of SVP Bankruptcy on Entrepreneurship (06:41) The Importance of Proper Risk Management (09:51) Absolute Focus on the Things You Can Influence (12:05) Managing a Global Team: Trust, diversity, and decentralized decision-making (14:56) Trusting the Best People (17:01) Hiring with Gut Feeling and CV-Application Letter Match (20:32) Marketing and Cultural Diversity (28:43) The Importance of Product-Market Fit Over Funding and Investors (29:12) Finding Customers vs Finding Investors (33:43) Milestones and Helping Customers (38:00) Talking to Customers About Their Problems (40:06) Identifying Markets and Competitors (42:56) Unlocking New Cancer Treatment Pathways (45:26) Overcoming Failure in Startups and Drug Discovery (48:49) Breaking Out of Confinement and Pursuing Goals (56:37) Impact of Upbringing on Entrepreneurial Spirit (57:33) Stop complaining, start improving: lessons from Vienna (01:00:04) Curiosity-driven education: finding a passion for physics (01:03:21) Experimenting in microgravity: sending projects to the ISS (01:14:20) Startup advice: focus on sales and steady growth (01:12:39) Overcoming adversity: believing in our technology (01:15:31) The potential of every disease being treatable (01:18:22) The impact of smoking on cancer risk (01:23:17) Leadership lessons: walking the talk and starting with yourself (01:26:35) Emotional Side of Leadership: How Emotions Drive Success (01:28:57) Balancing Kindness and Assertiveness in Leadership (01:31:49) Fostering Trust and Transparency in the Workplace (01:35:35) Maintaining the Spirit of Innovation While Scaling a Company (01:41:04) Struggles and Support from Business Angel Experience (01:42:13) Learning as a Business Angel: Insights and Expectations (01:45:01) The Impact of Toxic Behavior on Company Growth (01:48:56) Defining the Role of Business Angels in Startups (01:55:09) Balancing Executive and Investor roles (01:56:09) Investing in Teams You Can Trust (01:57:33) Building a Successful Company During Shutdowns (01:58:25) Advice t
#110: DC Palter - From Japan to Silicon Valley: A Unique Business Angel Journey
01:50:53
Unlock the secrets to startup success! Dive into an engaging conversation with DC Palter, a seasoned startup founder, CEO, and angel investor, as he shares invaluable insights and advice for CEOs and investors. Explore resilience, Japanese culture's impact on business, and innovative strategies. Don't miss out!
📖 Memorable Quotes: (14:42) "We need to think outside the box, have a goal, a dream; sometimes it works out spectacularly, and a lot of times it doesn't, but we tried and that's the building blocks for the next one." (42:23) "The number that's always quoted is “90% will fail”, but that doesn't mean fail outright. That means not succeeding as expected. About half of those will actually fail outright and give you no return, and then another four will give you something like your money back, maybe a little bit more, maybe a little bit less. So we call that a failure anyway, even though they haven't really completely failed." (01:01:56) "You can have a really simple idea, but if you have a lot of customers for it, if you know how to market it and build up a brand name, you can make a lot of money – and that's what investors are looking for." (1:27:57) "Marketing is about understanding the business, the market, and the customers, and becoming part of that community, so that customers find you." (1:48:07) “Embrace resilience, for every day is a challenge. You may be familiar with the English expression, 'three steps forward, two steps back.' However, in the world of startups, it's more like taking three steps forward and 2.9 steps back. Indeed, each day is a roller coaster ride.”
⏰ Timestamps: (01:46) Tea Ceremony, Japanese Culture, and Shared Interests (05:15) Who is Satoshi Nakamoto? (06:39) Silicon Valley Life, Work, and Writing Experience (07:22) Arnold Schwarzenegger and the Startup World (13:00) Tesla's Success: Overcoming Skepticism in Electric Vehicles (16:21) Theranos: Fake it Till You Make It (20:04) The Valley of Death: Challenges in Raising Money for Hard Tech Startups (24:42) Defining Financial Investor: Angel vs. Venture Capitalist (29:03) Investing in Startups: Balancing Personal Interests and Group Expertise (36:56) Uncovering success in the startup landscape (41:57) The long game of angel investing and managing expectations (48:23) The Mindset and Motivations of Angel Investors (56:34) Key Advantages of Angel Investments and Avoiding Startup Pitfalls (01:01:59) Crafting the perfect pitch: focus on product, market, and customers (01:07:09) Diversifying startup funding: alternatives to venture capital (1:12:12) Unraveling a Startup's Dark Secret: Discovering the True Intentions of Super Duper (1:19:20) Unexpected Love Triangle: Complex Relationships Amidst a Mysterious Investigation (1:24:05) The Importance of Social Media in B2B Marketing (1:29:57) Building an Effective Following and its Impact on Business (1:35:51) Building a Community on LinkedIn and Medium (1:39:04) Medium's Future: Business Model and Sustainability Concerns (1:48:00) Message to Startup Founders
MM3: Jeevan Sunner - Powerful Voices: The Rise of Female Leaders in Tech and Venture Capital
00:08:07
In this captivating episode of our podcast, we address the pressing issue of gender diversity within the tech and venture capital sectors, inviting Jeevan Sunner, a distinguished investor from Playfair Capital, to share her invaluable insights on the matter. Jeevan emphasizes the importance of promoting female representation in the industry and explores the vast opportunities that can arise from embracing diverse perspectives.
As CEOs and investors, understanding the immense value of nurturing a more inclusive environment is essential to unlock the full potential of the tech sector and maximizing investment returns. This episode sheds light on the challenges faced by women in tech and venture capital and discusses the actions that can be taken to create a more equitable landscape.
Tune in to this enthralling conversation and learn how your organization can foster change and benefit from increased diversity in the tech and venture capital fields. Don't miss this chance to listen to a leader who is spearheading the movement for inclusivity and championing the transformative power of gender equality in the tech world.
Subscribe to our podcast and stay informed on the latest trends and insights that will help you navigate the ever-evolving landscape of the tech and venture capital industries.
SP 7: From Villains to Vision: Unlocking Elon Musk's Powerwall Presentation Genius
00:09:12
Discover the secrets behind Elon Musk's captivating Powerwall presentation and learn how to engage your audience like a true visionary! Another special episode on the podcast unmasking presentation secrets.
In this episode, we dive deep into the art of storytelling, persuasion, and communication used by Musk during his groundbreaking Tesla Powerwall speech. Uncover the key techniques that made this presentation so influential and explore how you can apply them to captivate your own audience. 🚀
🔹 Time Markers: (00:36) Introduce a Villain (01:15) Agitate the Problem (01:51) Spark Intrigue (02:26) Offer the Missing Piece of the Puzzle (02:44) Show, Don't Tell (04:12)Sell Benefits, Not Features (05:01) Create Urgency (05:46) Build Trust (06:43) Demonstrate the Potential (08:02) Show Your Long-Term Vision
By analyzing these powerful moments, we'll unlock the keys to Elon Musk's presentation success. Learn how to inspire, educate, and captivate your audience, just like the Tesla CEO himself.
Don't miss this opportunity to transform your own presentations and make a lasting impact! 🌍🔋
MM4: Philipp Baaske - From Science Fiction to Microgravity: Nanotemper's Journey to the International Space Station
00:10:01
Discover the groundbreaking journey of Nanotemper Technologies as CEO Philipp Baaske shares his passion for space exploration, science fiction, and the company's ambitious project aboard the International Space Station. Learn how microgravity is poised to revolutionize biotech research and redefine our understanding of protein stability. Don't miss this exclusive conversation with one of the most innovative minds in the industry!
Quote: (02:44) "To really understand what temperature alone does to [antibodies] without flows, you have to switch off gravity, which you can't do on Earth. But on the International Space Station, with microgravity, there's nearly no influence of gravity, so we can study the stability of antibodies without the influence of gravity or thermal convective flows."
⏰ Timestamps (00:44) Passion for Space Exploration: Star Trek, Star Wars, and SpaceX (03:25) Organizing a Space Project: Collaboration and Opportunities (05:16) Pursuing Exciting Projects for Fun and Scientific Advancement (06:39) Inspirations from Science Fiction: Isaac Asimov's Lucky Star
#111: Colin McCann Reveals Game-Changing Vaccine Strategies at IVI
01:41:12
Are you tired of seeing the world struggle with global health crises? It's a harsh reality that many vaccine-preventable diseases continue to devastate vulnerable populations. But there's hope on the horizon!
In this eye-opening episode, we dive deep into a conversation with Colin McCann, a key player at the International Vaccine Institute (IVI), who shares incredible insights into their innovative approach to combatting these health challenges. You'll discover the groundbreaking strategies and collaborative efforts reshaping how we develop and deliver life-saving vaccines to those who need them most.
Don't miss out on this unique opportunity to learn about the future of global health and how the IVI is making a real difference. Click now to watch the full episode and get inspired!
(29:30) "IVI's role is to pick up challenges that the pharma industry would turn down, starting with comprehensive disease burden studies and surveillance to determine the true burden of neglected diseases." (40:02) "There's the great problem of the translational graveyard - we have lots of wonderful vaccine candidates sitting on shelves around the world collecting dust, instead of saving lives." (41:47) "European developers should realize that they could manufacture their vaccines in Africa, Latin America, or Asia and maintain profitability in doing so." (55:51) "Countries that are often in tension with each other are able to cooperate on vaccine development." (01:01:46) "By linking low & middle income countries together, they can train each other and build upon each other's abilities." (01:18:44) "IVI's proven model: developing a vaccine from evidence through licensure & delivery, takes a comprehensive approach."
⏰ Timestamps: (02:28) Vienna: The Hub for IVI's European Expansion (07:55) The Unconventional Path to Joining the International Vaccine Institute (11:09) Colin's journey: From wind turbine engineer to IVI member (17:51) Bridging the gaps in vaccine development and scaling (21:47) IVI's role in growing South Korea's biotech sector (28:31) IVI's Role in Addressing Unmet Vaccine Needs (35:56) Exploring IVI's Role in Clinical Development and Vaccine Manufacturing (38:31) Facilitating Industry Partnerships and Filling Global Health Gaps (42:42) Attracting Private Investors and Venture Capital in Vaccine Development (45:50) The Role of CEPI in Addressing the Funding Gap for Vaccine Development (49:35) ASEAN: Coordinating Vaccine Development and Streamlining Regulations (54:58) Vaccine Diplomacy and Capacity Building in Africa (57:00) Strengthening Healthcare Systems through Training (01:00:10) South-South Triangular Cooperation for Capacity Building (01:05:17) Combating Mosquito-Borne Diseases in Latin America (01:10:51) Tackling Complex Zoonotic Diseases: A Holistic Approach (01:14:49) Ensuring Sustainability: Empowering Local Communities (01:19:30) Overcoming Policy Tunnel Vision: A Comprehensive Vaccine Lifecycle Approach (01:22:36) Holistic Long-Term Decision Making in Global Health (01:24:44) Government Collaboration in Tackling Global Health Challenges (01:31:46) IVI's Expansion to Austria: Enhancing Research Cooperation (1:34:50) Impactful Partnerships in Global Health (1:36:18) Innovations: Encapsulation, Vaccine Patches, a
SP8: The Art of Successful Investing: Lessons from Mohnish Pabrai
00:15:25
Navigating the investment landscape can be a daunting task. It's easy to feel like you're constantly making the wrong moves and not achieving your financial goals. This episode brings you the wisdom of legendary investor Mohnish Pabrai, who shares his insights on overcoming these hurdles and achieving success in investing.
Here's what you can expect from this episode:
Understanding Cognitive Biases Time Marker: (01:44): Our brains, evolved over millennia, are not naturally wired for investing. Mohnish Pabrai explains how understanding our cognitive biases can help us become better investors.
The Importance of Patience Time Marker: (03:28): Successful investing requires a long-term approach and a willingness to hold on to great businesses. Pabrai shares his thoughts on why patience is a virtue in investment.
Lifelong Learning Time Marker: (05:04): The investment landscape constantly changes. Pabrai emphasizes the significance of continual learning in staying ahead in the investing game.
By the end of this episode, you'll better understand how to navigate the investment landscape and make more informed decisions. So, tune in, take notes, and let's embark on this journey to financial growth together.
Don't forget to share this episode with your friends and colleagues who might find it useful. And if you enjoyed this episode, please leave us a review. Your feedback helps us improve and reach more people like you.
#112: BIO's Rich Masters on the Future of Biotech and the International Convention
01:12:50
Navigating the biotech industry's rapid advancements and complex regulations can be daunting. High-stakes investments and the pressure to innovate further add to the challenge.
Rich Masters, the CMO of BIO (Biotechnology Innovation Organization), is a seasoned expert in this field. His role in organizing the BIO International Convention and his extensive industry experience equips him with unique insights to tackle these challenges.
In this fantastic podcast episode, we delve into:
🔬 The behind-the-scenes experience of organizing and attending the BIO International Convention 2022 in San Diego. 🔬 Rich's journey to the helm of BIO as CMO and his vision for the organization. 🔬 The meticulous preparations for the upcoming BIO International Convention 2023 in Boston, anticipated to be a landmark event in the biotech calendar. 🔬 The innovative features and services introduced for the BIO International Convention 2023, including the BIO Podcast series and the BIO News platform. 🔬 Rich's perspective on the future of the biotech industry, discussing potential challenges and opportunities for 2024 and beyond.
📖 Memorable Quotes: (13:50) "The majority of biomedical and drug innovation investments fail... This ecosystem is crucial and needs protection." (15:00) "Developing a drug is an expensive process... Without investment, the engine of innovation stalls, we don't see new drugs on the market." (16:38) "If you price fix these drugs, you are going to stop the cures of the future." (20:01) "What we're witnessing worldwide is an attack from socialist-minded groups against intellectual property, our only asset." (26:18)"Our main focus may be on Washington, but we work closely with our International Biotech Association based in Brussels. We have numerous international partners." (29:09) "As the next pandemic looms, the question is, do we want all drug development concentrated in one country, or a viable drug development market in the West?" (42:12) "We can't continue to stifle innovation and science and then expect to create the next generation of cures... we're eliminating entire classes of diseases." (44:10) "Biotechnology provides the solution for eliminating food insecurity, transitioning from fossil fuels to green energy sources, and ending disease... we need to establish policies that encourage, rather than stifle, innovation."
⏰ Timestamps: (03:45) - [Recap: BIO Convention Collaboration Success] (05:18) - [BIO Event Excellence: Future Planning Insights] (10:36) - [Inside BIO: CMO's Role & Event Portfolio] (17:05) - [Decoding Biomedical Investment Ecosystem] (20:31) - [Behind BIO Conventions: Passion & Effort] (22:15) - [Biotech Investment: Price Fixing & IP Challenges] (27:41) - [Capital Formation in Biotech: Navigating Economic Shifts] (29:33) - [Global Biotech Politics: Washington & Brussels Focus] (32:24) - [Future of Drug Development: Market Shift Navigation] (35:32) - [BIO 1-1 Partnering: Revolutionizing Biotech Startup Growth] (42:54) - [Policy Impact & Transition to Physical Conventions] (47:25) - [Biotech Solutions: Hunger, Climate, Disease] (51:32) - [Bio Convention Revolution: Aggressive Marketing Strategy] (55:57) - [Middle East Evolution in Global Innovation Scene] (59:30) - [Balancing Attendee Expectations: The Art & Challenges] (01
MM 5: Rich Masters - Investing in Biotech: Risks, Rewards, and Realities
00:06:46
Entrepreneurs and investors often grapple with the complexities of the biotech industry. The high risk associated with drug development, coupled with the intricate regulatory environment, can make biotech investments seem daunting. Moreover, the need for substantial capital and the long timeline for potential returns can further complicate the investment decision.
This clip provides a comprehensive overview of the biotech investment landscape, offering valuable insights from industry experts. By watching this clip, you will understand the challenges and opportunities in biotech investments, learn about the importance of patient capital, and discover strategies to mitigate risks. This knowledge can empower you to make informed investment decisions, potentially leading to high returns and contributing to advancements in healthcare and medicine.
📖 Quote: (04:44) And we would have lost all of our money. And that's what investors have to go through every day. And so we're trying to put it in language so that every Joe understands that if you price fix these drugs, you will stop the cures of the future.
⏰ Timestamps 00:00:00 "High Stakes in Biotech Investing" 00:01:24 "Standing Up for Science" 00:02:36 "Price Fixing Stifles Innovation"
MM 6: Sebastian Mallaby: The Art of Storytelling in Venture Capital
00:06:17
Welcome back to another episode of Memorable Moments. Today's spotlight is on the conversation with Sebastian Mallaby, acclaimed author of 'The Power Law'.
Venture capital, often a labyrinth of jargon and complex concepts, is made accessible through Mallaby's unique storytelling approach. This episode reveals the meticulous process behind his writing, showcasing the comprehensive research and interviewing methods that shape his work. It's a testament to the power of storytelling in making even the most complex subjects engaging.
The journey continues with the uncovering of the stories behind venture capital. These narratives, brought to life through Mallaby's exceptional storytelling, offer a fresh perspective on the world of venture capital.
Curiosity about the evolution of venture capital or a simple appreciation for great storytelling makes this episode a must-listen. This memorable moment with Sebastian Mallaby invites listeners to immerse themselves in the fascinating world of venture capital. Listen now, and let the journey begin.
MM7: Behind PayPal's Triumph: Jimmy Soni on Elon Musk, Peter Thiel, and the Paypal Mafia
00:04:45
Dive into the untold stories of PayPal's meteoric rise!
This video takes you back to the 90s, a time when the internet was just beginning to transform business. It was a challenging era, with limited access to information and a lack of understanding about the potential of the internet.
Fast forward to today, and we see the fruits of the labor of PayPal's founders. They not only survived the dot-com bubble but also thrived, becoming some of the most influential figures in the tech industry.
How did they do it? What lessons can we learn from their journey?
This video explores how PayPal's founders drove 21st-century innovation and entrepreneurship, forming, funding, and advising some of the leading companies of our era, including Tesla, Facebook, YouTube, Space X, Yelp, Palantir, and LinkedIn.
Tune in to discover the secrets behind their success, gain unprecedented insights from hundreds of interviews and thousands of pages of internal material, and learn how you can apply these lessons to your own entrepreneurial journey. Don't forget to like, share, and subscribe for more inspiring content!
#113: Kimberley Miner: A Climate Change Journey from Everest to NASA
00:44:46
In a world on the brink of climate catastrophe, one woman stands at the forefront of scientific discovery and action. "We found the highest microplastics in the world on Mount Everest, a sad Guinness World Record to hold," reveals Dr. Kimberley R. Miner in this gripping episode.
Dr. Miner is a Climate Scientist and Program Manager at the NASA Jet Propulsion Lab, a Guinness World Record holder, and an adventurer who has braved the extreme environments of the North Pole, Antarctica, and Mt. Everest. Her groundbreaking research on climate risks has garnered international recognition, with features in the BBC, NYT, and GQ.
This episode takes you on a journey from the icy slopes of Everest to the cutting-edge labs of NASA. It delves into the pressing issues of climate change, the surprising discovery of microplastics at extreme altitudes, the role of art in science communication, and the importance of diverse perspectives in tackling global challenges. It also offers a sneak peek into Kimberley's upcoming book on how younger generations can plan for climate change.
This is a riveting exploration of our planet's most pressing issue, through the eyes of a scientist who has literally seen it from top to bottom. A must-listen for those seeking to understand the real-world implications of climate change and the solutions that science and innovation can offer.
📖 Memorable Quotes: (00:07:00) "We're changing Earth's dynamics faster than ever before." (00:15:36) "We can create a healthier, more natural planet with advanced tools." (00:24:15) "Forecasting changes due to climate change is a monumental task." (00:40:39) "Stop releasing carbon, dedicate land to wilderness, and engage in conversations about our planet's reality."
⏰ Timestamps: (0:00) Kickoff (4:53) Current Status of Climate Change: A Global Perspective (8:22) The Sixth Mass Extinction: Biodiversity Loss and Ecosystem Collapse (11:11) Unveiling the Power of Emit: NASA's Methane Tracker (16:07) The Journey to Becoming a Climate Scientist at NASA (21:03) The Arctic Methane Challenge: A Collaborative Effort (22:22) Unraveling the Climate Crisis - Microbes, Methane and Melting Permafrost (25:29) The Immediacy of Climate Change - A Matter of Decades (29:43) The Invisible Threat - Toxic Chemicals in a Changing Climate (33:30) Unveiling the Highest Microplastics on Mount Everest (36:30) The Top Three Actions to Combat Climate Change (42:47) The Role of Biodiversity in Addressing Climate Crisis
MM 9: Tobias Silberzahn on Unlocking Mental Well-being: Sleep, Nutrition, Mobility, Fitness, and Purpose
00:07:01
Join Tobias Silberzahn, a Partner at McKinsey's Berlin office and a leader in the global Health Tech Network, as he delves into the crucial role of lifestyle habits in maintaining mental health and well-being.
In this enlightening talk, Tobias discusses the importance of sleep, nutrition, mobility, fitness, and purpose, providing practical advice that viewers can apply in their daily lives. He also explores the biochemical processes involved and the effects of sleep deprivation and lack of movement on anxiety levels.
Don't miss this opportunity to learn from a leading expert in healthcare innovation and digital transformation.
Is investing in climate tech just a trend, or is it the future of venture capital? Doerte Hirschberg, a leading figure in the VC world, challenges the status quo and brings a fresh perspective to these questions.
Doerte Hirschberg is the co-founder and managing partner of Climentum Capital, a venture capital firm that focuses on climate tech investments. With a background in traditional investments, she has transitioned into the climate tech space, bringing with her a wealth of knowledge and a unique perspective on the intersection of business viability and environmental sustainability.
In this episode, we delve into:
The transition from traditional investments to climate tech.
The intersection of climate tech and business viability.
The role of women in venture capital and the gender gap in VC investment.
The role of regulations and capital in shaping Europe's climate tech future.
Balancing work and family life in the demanding world of venture capital.
Don't miss out on this insightful conversation. Subscribe to our channel and join us in exploring the future of climate tech investing with Doerte Hirschberg.
📖 Memorable Quotes: (04:49) "Installing solar and investing in energy-saving technologies make sense from a business case point of view." (15:04) "Climate change and CO2 emissions are measurable impact topics, making our fund's impact target as credible as our financial ones." (35:04) "In the VC investment field, you mostly have male teams or one woman, especially in the industrial sector." (39:17) "The traditional venture capital game is about the winner. Women, making up 50% of consumers, can see many trends and insights more clearly." (01:06:37) "My aspiration is a transition towards a more sustainable industry and society, reducing extreme poverty and maintaining Earth as a livable place."
⏰ Timestamps: (00:01:00) Initiating Discussion on Climate Change Investments (00:02:42) Transitioning from Traditional Investments to Climate Tech (00:05:33) The Intersection of Climate Tech and Business Viability (00:12:02) Exploring the Power of University Innovations (00:14:10) The Art and Science of CO2 Investing (00:20:16) The Intersection of Technical Expertise and Global Reach (00:26:02) Pragmatism in Green Transition (00:30:02) The Role of Capitalism in Green Innovation (00:34:02) Embracing Diversity in the Green Sector (00:38:47) Risk Aversion: Women as Better Investors? (00:40:07) Closing the Gender Gap in VC Investment (00:46:06) The Role of VCs in Startup Success and Growth (00:51:14) Unveiling the Unique Selling Proposition in Venture Capital (00:52:13) The Journey of a New Fund: From First Closing to Future Aspirations (01:01:32) The Role of Regulations and Capital in Shaping Europe's Climate Tech Future (01:05:46) Investing in Venture Funds: The Right Time and Momentum (01:06:37) Vision for a Sustainable Future: From Dreams to Reality (01:09:08) Investing in Innovation: The Case of Vegan Cheese (01:20:58) Harnessing Power and Energy from Diverse Engagements (01:22:46) Efficiency in Balancing Work and Family Life (01:25:24) The Role and Impact of White Papers in Investment
MM10: Philipp Baaske - Believe, Invest, and Grow: A Conversation with NanoTemper's CEO
00:10:18
"Believe in the team, invest the money." This is Philipp Baaske, founder and CEO of NanoTemper Technologies.
His company, a global biotech powerhouse, is on a mission to create a world where every disease is treatable.
Philipp's journey from a small Bavarian village to leading a global team of 240 is inspiring. His company now generates over 35 million in annual revenue.
His secret? Start small, dream big, and invest profits back into the business. In this clip, Philipp shares his insights. He talks about the importance of angel investors in startups.
They're not just financial backers. They're partners. They're believers in the team and the vision.
His story echoes the audacity of tech giants. Like Bill Gates selling an operating system before it was fully developed. Like Steve Jobs' relentless focus on customer experience at Apple.
Join us for this enlightening conversation. Philipp offers a rare glimpse into the world of startups. He talks about the dynamics between startups and their angel investors. He emphasizes the importance of trust.
Click play. Dive into the world of startups and angel investing.
Don't forget to subscribe for more insights! This is a conversation you won't want to miss.
SP 10: Warren Buffett's Wisdom on Emotional Discipline: Highlights from the 2023 Berkshire Hathaway Meeting
00:06:04
Ever feel like your emotions are driving your investment decisions? You're not alone. It's a wild ride in the investment world, and it's all too easy to let our emotions take the wheel. But here's a secret from two of the greatest investors of our time, Warren Buffett and Charlie Munger.
In this clip from the 2023 Berkshire Hathaway Shareholder Meeting, they spill the beans on how they keep their emotions in check. They've made their fair share of bad investment decisions, but they've never let their emotions dictate their choices.
This is a game-changer, folks. The market is a roller coaster, and if we let fear and greed take over, we're in for a bumpy ride. But Buffett and Munger remind us to stay cool, calm, and collected.
Investing isn't about making a quick buck or panicking when things go south. It's about making smart choices based on solid research and sticking to your guns, even when the market is doing somersaults.
So the next time you feel your heart racing or your palms sweating over your investments, take a deep breath and channel your inner Buffett. Keep those emotions in check, stay disciplined, and keep your eyes on the prize.
Check out the clip to hear it straight from Buffett and Munger. And don't forget to share it with your fellow investors. The more we learn, the better we can navigate the wild world of investing.
MM 12: Marco Schmidt - The Future of Drug Discovery: Biotx's Predictive AI Approach
00:06:32
Ever wondered how AI is revolutionizing drug discovery?
Dive into this insightful conversation with Marco Schmidt, the brilliant mind behind Biotx.ai.
As the CSO, Marco has been at the forefront of leveraging AI and genetics to predict drug success. In this clip, he shares his journey from data interpretation to predictive statistics, the inception of Biotx.ai, and the transformative impact of artificial intelligence on drug development.
Discover the future of medicine and the role of AI in shaping it.
If you find this intriguing, don't forget to like, comment, subscribe, and share.
#115: Daniel Vitt - Pioneering Patient Care: Dr. Daniel Vitt on the Future of Medicine
01:35:33
Is revolutionizing patient care through biotechnology an ambitious dream, or is it the future of medicine? Dr. Daniel Vitt, a leading figure in the biotech world, challenges the status quo and brings a fresh perspective to these questions.
Dr. Daniel Vitt is the CEO of Immunic Therapeutics, a company at the forefront of developing groundbreaking treatments for chronic inflammatory and autoimmune diseases. With a background in molecular biology and a passion for innovation, he is steering Immunic towards a future where patients have more effective and safer treatment options.
In this episode, we delve into:
• The visionary approach of Immunic Therapeutics in treating multiple sclerosis and leaky gut. • The challenges and triumphs of bridging European and American biotech markets. • The role of serendipity in scientific discovery and innovation. • The future of Immunic: clinical trials, stock prices, and global expansion. • Daniel’s three key lessons for anyone daring to start their own company in the biotech industry. • Don't miss out on this insightful conversation. Subscribe to our channel and join us in exploring the future of biotech with Dr. Daniel Vitt.
📖 Memorable Quotes: (00:02:23) "Every morning, when I go to work, I enjoy being part of an industry that improves patients' lives." (00:05:26) "Understanding the key and lock principle in biology is our path to curing diseases." (00:24:49) "Serendipity means you're searching for a needle in a haystack, but you find something unexpected and even more valuable." (01:13:23) "If you are early and have a big vision, you can succeed easily." (01:32:35) "Expect the unexpected and be prepared. Adaptability is key in our rapidly changing industry."
⏰ Timestamps: (00:01:15) Unveiling the Future of Patient Care (00:05:26) Decoding the Key-Lock Principle in Biology (00:11:16) The Dynamic Dance of New Technologies in Healthcare (00:16:54) Misconceptions: Multiple Sclerosis vs. Parkinson's (00:17:41) Exploring the Link: MS, Parkinson's, and Neurodegeneration (00:24:15) The Power of Serendipity in Scientific Discovery (00:35:07) Addressing Celiac Disease: A New Approach (00:39:10) The Challenges of Multicenter Multinational Studies (00:48:49) A Potential Game-Changer: Restoring the Gut (00:50:38) Western Lifestyle's Impact on Gut Health (00:52:18) The Balance of Lifestyle and Disease (01:02:12) The True Cost of Drug Development (01:08:31) Unveiling a Multi-Billion Opportunity: The Market Potential (01:12:40) The Bavarian Biotech Boom: A Tale of Visionary Politics (01:22:31) Crossing the Atlantic: European Biotech’s Path to U.S. Success (01:23:51) Navigating the Global Biotech Landscape: Daniel Vitt's Perspective (01:26:41) The Next Leap: Interim Analysis of a Pivotal Phase Two Study (01:32:35) Adaptability in Biotech: Learning from Biontech's Success Story
SP 11: Unlocking the Investor's Dilemma: Buffett & Munger's Wisdom from Berkshire Hathaway 2023 Meeting
00:19:25
In this special episode, we bring you exclusive insights from Warren Buffett and Charlie Munger, straight from the Berkshire Hathaway 2023 Shareholder Meeting. They tackle the age-old investor's dilemma:
How to balance short-term profits with long-term sustainability. Whether you're a retail investor or running a multi-billion dollar fund, this episode is packed with wisdom you won't want to miss.
🎧 Don't forget to leave us a review and share this episode with your network! 🎧 Subscribe for more exclusive content from industry leaders. 🎧 Special thanks to our sponsors. Check out the companies that make this podcast possible!
MM 13: Samantha Dale Strasser - Revolutionizing Drug Discovery: The Startup That's Changing the Game
00:07:25
"Are you tired of the long, winding road of drug discovery, full of dead-ends and costly detours? Do you wish there was a more efficient way to navigate the complex landscape of pharmaceutical R&D?
In this episode, we bring you the solution that promises to be the 'Google Maps' for drug discovery. Samantha Dale Strasser, PhD, CSO and co-founder of Pepper Bio, shares her revolutionary approach to drug discovery that's already making waves in the healthcare industry.
#116: Yair Reem - From Net Zero to Gigatons: The Extantia Capital Blueprint for Climate Tech Investing
02:02:29
Did you know that the fight against climate change is shaping up to be the biggest business opportunity since the rise of the internet?
Imagine a multi-trillion-dollar market waiting to be tapped! Yair Reem and his €300M venture capital firm, Extantia Capital, are not just imagining it—they're building it.
Tune in to discover how you can be part of this green gold rush! 🎙️ What's in the Episode: 1️⃣ The Urgency of Climate Change: Yair discusses why climate change is not just an environmental issue but a ticking time bomb that affects every sector of the economy. 2️⃣ The Role of Venture Capital: Learn how Extantia Capital is more than just a fund—it's a €300M platform that unites mission-driven entrepreneurs, scientists, and business leaders to advance the transition to a greener future. 3️⃣ The Multi-Trillion Dollar Opportunity: Yair shares insights into how the fight against climate change creates unprecedented business opportunities, potentially even 100x bigger than the internet revolution.
👨💼 About Yair Reem: Yair Reem is more than an investor; he's a builder. From childhood Legos to Electrical Engineering and co-founding Extantia Capital, his path is fueled by a drive to make impact. With experience on both sides of investment, he knows what makes a firm succeed. His motto, "Do well by doing good," shows his belief that profit and impact can coexist.
📌 Quotes: (21:10) "The technologies we have today can only take us halfway to net zero emissions. There's a lot of technology that still needs to be developed and scaled to make it ready for the mass market." (23:38) "To bridge the 50% gap in fighting climate change, we need to deploy capital to motivate scientists to develop new solutions and companies to scale those solutions." (57:58) "When we look at the intersection of public and private sectors, we see that regulators are essential for both basic research and for making certain industries profitable where they currently aren't. But the key question remains: How do we ensure that these profits are reinvested to drive down costs and improve processes, rather than being siphoned off for other uses?" (1:07:08) "The worst time to raise money is when you need it; the best time is when you don't." (1:36:32) "We don't just take a good team and build a good product with them; we take a good team with a good product and help make that an excellent business." (2:01:12) "My wish is that we will see much more peace in the future, thanks to ubiquitous and cheap energy."
⏰ Timestamps: (03:30) Yair Reem's Journey: Electrical Engineering to Climate Tech (09:33) Urgency of Climate Change (21:10) Tech Gap: Net Zero Emissions by 2050 (22:06) Tech Innovation in Climate Change (23:38) Bridging the 50% Gap (30:36) Sustainability, Growth, Social Justice (40:38) Short-Term Sacrifice for Long-Term Gain (42:31) Role of Regulation in Climate Solutions (48:47) Financial Returns in Climate Investments (59:01) Airline Profits: Bankruptcy to Flourishing (1:03:34) The Tim Cook Effect (1:13:02) VC Ecosystems: Secret Sauce (1:19:57) Art of Syndication in High-Stakes (1:28:35) Retrofitting the Future (1:39:40) Uninvestable Cap Tables (1:40:56) Negotiating Equity with Universities (1:47:44) Double-Edged Sword of Secondary Investments (2:01:05) Future of Energy: Ubiquitous, Free Access
SP 12: Andrew Huberman - 🚨 The Silent Crisis: Why 70% of the U.S. and Europe are Vitamin D Deficient 🚨
00:08:49
Are you part of the 70%? Vitamin D deficiency is a silent crisis affecting both the U.S. and Europe. The lack of this essential nutrient can lead to severe mental health issues, including depression and anxiety, due to its role in serotonin production. Physical health is also at risk, with increased chances of respiratory issues and even cancer. In this eye-opening episode, we delve into the Huberman Lab Podcast, where Dr. Andrew Huberman and his guest Dr. Rhonda Patrick, discuss the alarming rates and severe health consequences of Vitamin D deficiency.
Who are Dr. Andrew Huberman and Dr. Rhonda Patrick? Dr. Andrew Huberman is a renowned neuroscientist and professor at Stanford University. His guest, Dr. Rhonda Patrick, is an expert in nutritional health. Together, they unpack the science behind Vitamin D, its crucial role in our body, and why you should be concerned about your Vitamin D levels.
Who Needs to Watch This? If you care about your mental and physical health, this episode is a must-watch. Whether you're in the U.S. or Europe, young or old, the information here is vital for everyone.
What You'll Learn:
The science behind Vitamin D and its production in our body
How Vitamin D affects your mood and immune system
The relationship between skin color and Vitamin D production
Practical tips for proper Vitamin D supplementation
Timestamps: (01:22) Introduction to Vitamin D's Importance (01:46) Vitamin D and Skin Color (03:17) Vitamin D Deficiency in the Population (04:49) Vitamin D and Gene Regulation (04:59) Vitamin D and Serotonin (07:15) Importance of Testing Vitamin D Levels (07:27) Vitamin D Supplementation Dosage
Take Control of Your Health Don't be part of the statistics. Consult your physician or pharmacy today to get your Vitamin D levels checked. Your health is in your hands.
🎧 Don't forget to leave us a review and share this episode with your network! 🎧 Subscribe for more exclusive content from industry leaders. 🎧 Special thanks to our sponsors. Check out the companies that make this podcast possible!
MM 14: Prof. Alexander Wurzer - Why Most Digital Innovators Fail at Patenting Their Tech
00:07:43
The digital age has brought forth a plethora of opportunities, but with it comes a maze of complexities, especially when it comes to patenting digital innovations. Many tech-savvy entrepreneurs find themselves lost, patenting solutions that are either meaningless or purely artificial. But what if the problem isn't with the technology, but with the approach?
🔹 Discover the Misconceptions: Understand why starting with technology can lead you astray and how a customer-centric approach is the key. 🔹 The AI Paradox: Dive into the intricacies of patenting AI and why mentioning the tech might not always be the best strategy. 🔹 Real-world Examples: Learn from a groundbreaking patent involving salmon and lasers, illustrating the essence of unique patenting.
Meet Prof. Alexander Wurzer, a luminary in IP management and a professor at CEIPI, University of Strasbourg. With a rich tapestry of over 200 publications and a revolutionary method in IP design, he unravels the enigma of intellectual property in the digital realm.
📢 If this resonates with you or sparks your curiosity, hit that subscribe button and dive deeper into the world of digital patenting with us. Your support amplifies our mission to bring more insights like these to the forefront.
#117: Jon Chee - Disrupt, Ask, Innovate: Inside Jon Chee's Mindset
02:02:11
🎯 Challenging the Biotech Status Quo with Jon Chee of Excedr! Dive into a transformative conversation with Jon Chee, the CEO and Co-founder of Excedr, as he shares his journey from the wet labs of UC Berkeley to revolutionizing the way life science startups access mission-critical equipment.
🚀 Main Points: 1️⃣ The Excedr Mission: Discover how Excedr is bridging the gap between life sciences and financial services, offering founder-friendly equipment leases to accelerate high-impact research. 2️⃣ The Power of Leasing: Uncover the benefits of leasing over purchasing, from improved cash flow to accelerated research timelines. 3️⃣ The Vision for the Future: Jon's long-term vision for Excedr and how it aims to improve health outcomes globally.
👤About Jon Chee: With over a decade in the life sciences industry, Jon Chee co-founded Excedr to alleviate the financial burdens faced by early-stage life science companies. His academic background in Molecular Toxicology from UC Berkeley and his passion for entrepreneurship drive his mission to support groundbreaking research.
🗣️ Top Quotes from Jon Chee: (00:12:45) "Entrepreneurship started when I wanted to alleviate obstacles impeding our lab's ability to research." (00:28:41) "I enjoy challenging the status quo and constantly asking, 'Why?'" (00:56:34) "Having a mission you truly believe in makes facing rejection worthwhile." (01:09:03) "Finding win-win situations is more than just business; it's about living a life worth remembering." (01:45:58) "Over time, challenges net out and head in the right direction. As long as our North Star is clear, we'll be just fine."
⏰ Timestamps: (00:02:26) The Art of Starting a Podcast: Joe Rogan and Lex Fridman (00:06:31) Conversations Over Drinks: The Essence of Podcasting (00:13:13) From Gaming to Entrepreneurship: A Journey of Building (00:15:35) The Art of Game Theory in Poker (00:16:28) Disrupting Predictable Strategies (00:19:39) Poker's Parallels to Business and Investing (00:28:41) Challenging the Status Quo: The Power of Asking Why (00:29:56) Growing the Pie: Value for All Stakeholders (00:38:22) Expanding Horizons: Serving the US Research Community (00:42:03) Navigating Europe's Complex Landscape (00:43:51) The Entrepreneurial Shift: Berkeley vs. Stanford (00:51:56) Bridging the Gap: Science Meets Finance (00:54:22) "Embracing the Village Mentality in Science" (00:56:34) "Mission-Driven Persistence Amidst Rejection" (01:04:48) "Defining Value in Stakeholder-Centric Deals" (01:07:05) Building for a 100-Year Journey (01:08:39) Living Life with Win-Win Situations (01:14:42) Demystifying Entrepreneurship in Science (01:20:53) Improving Health Outcomes: A North Star (01:21:52) The Digital Revolution: Global Accessibility and Connection (01:29:40) Navigating Financial Challenges in Startup Ecosystems (01:34:36) Deep Dive into Lab Equipment Financing (01:37:01) Distributed Bio: A Success Story (01:44:36) The Future of Venture Capital in Silicon Valley (01:48:18) Europe's Unique Science Funding Landscape (01:49:43) U.S. Ecosystems Beyond Silicon Valley (01:56:45) Nurturing Biotech Leaders with nucleate.xyz
📣 Looking to extend your cash runway and get the equipment your lab needs? Excedr offers flexible leasing solutions tailored to your needs. Dive into a worl
SP 13: Christian Soschner - Why Top Entrepreneurs Don't Have a Plan B - And You Shouldn't Either!
00:05:41
Ever find yourself constantly contemplating a fallback? That nagging thought of a Plan B might just be what's holding you back from true entrepreneurial success. Many top achievers know that to excel truly, you need an all-in mindset.
In this episode, you'll discover the seven core principles from the groundbreaking book "Burn the Boats" that have transformed the journeys of countless entrepreneurs. Dive deep into a mindset shift that could redefine your path to success and understand why having a safety net might be your biggest setback.
The insights are based on the book "Burn the Boats" by Matt Higgins, a battle-hardened entrepreneur with a track record of success.
Your narrator, Christian Soschner, isn't just an avid reader but a seasoned executive coach with over 30 years of experience. As the host of the 'Beginner's Mind Podcast' and with a vast network spanning life sciences, biotech, and deep tech, Christian brings a wealth of knowledge and insights to the table. His mission? To share transformative business wisdom with you.
Don't miss out on these game-changing strategies. Listen to the full episode now and embark on an unyielding path to your entrepreneurial triumph!
MM15: Alexander Valtingojer - Unlocking the Metaverse's Potential: The Crypto-Fintech Fusion Entrepreneurs Need to Know!
00:10:52
🔥 The Metaverse is more than just a digital realm; it's a goldmine waiting to be tapped. But how can entrepreneurs and investors navigate this new frontier without getting lost?
1️⃣ The Problem Amplified:
Are you struggling to understand the convergence of crypto and fintech in the Metaverse?
Feeling overwhelmed by the rapid technological advancements and unsure how to capitalize on them?
Concerned about missing out on the next big opportunity in the digital economy?
2️⃣ What You'll Get in This Clip:
Insights into the fusion of crypto and fintech within the Metaverse and its implications for businesses.
Strategies to leverage these technologies for maximum profit and growth.
Expert advice from Alexander Valtingojer, a pioneer in the field, to guide your entrepreneurial journey.
3️⃣ About Alexander Valtingojer: Alexander Valtingojer is the CEO of the crypto fintech Coinpanion. From his school days, he was deeply involved with cryptocurrencies, leading him to work on various projects in this domain. He developed a Bitcoin PayPal marketplace and later, during his studies, actively traded cryptocurrencies. Alexander even worked on his own ICO and spoke at the C³ Crypto Conference in Berlin.
Subsequently, he founded a sole proprietorship for software services. For the past four years, he has delved deep into the financial markets and was a trader on Coinpanion's previous version. Today, Coinpanion has grown into a thriving company with 30+ employees, aiming to assist everyone in entering the crypto market with smart portfolios.
📢 Engage with Us!: If you found this content valuable, please subscribe, like, comment, and share. Your support helps us bring more insightful content and attract thought leaders to share their expertise.
🎉 Enjoy the Clip: We hope you find this video enlightening and beneficial. Dive deep into the world of the Metaverse and discover the opportunities that await!
#118: Ash Ravikumar - Beyond the Collider: CERN's Blueprint for Startup Breakthroughs
02:03:54
🎯 Empowering Entrepreneurs with Ash Ravikumar! Join us for an enlightening conversation with Ash Ravikumar as he delves deep into the world of tech transfer, the essence of entrepreneurship, and the pivotal role of academics in innovation.
🚀 Main Points: 1️⃣ Optimizing Entrepreneurial Time: Ash's unique approach to maximizing time and processes to uplift entrepreneurs and startups. 2️⃣ The Heart of Tech Transfer: The indispensable role of academics and the trust dynamics in the tech transfer landscape. 3️⃣ Global Technological Race: Ash's insights on Europe's fragmented approach and the need for a unified front to rival tech giants like the USA and China.
👤 About Ash Ravikumar: A visionary with a keen sense of innovation, Ash Ravikumar has been at the forefront of tech transfer, emphasizing the importance of academics and trust. With a passion for optimizing processes, he champions the cause of entrepreneurs, ensuring they have the tools and support to succeed.
🗣️ Top Quotes from Ash Ravikumar: (00:03:15) "Life is beautiful; if our only complaint is about the weather, then life is truly good." (00:57:26) "Success is not by chance; it's designed." (01:12:16) "You won't compete with a large, unified country moving at a fast pace." (01:55:59) "You're good at what you do. Seek experts outside of your realm; you don't have to understand everything." (02:01:13) "Our only hope for addressing challenges, from climate change to poverty, lies in science."
⏰ Timestamps: (00:03:15) Life's Beauty: Embracing Challenges and Weather (00:09:56) The Serendipity of Tech Transfer and Global Impact (00:14:23) Optimizing Time for Entrepreneurial Success (00:20:50) Navigating IP Challenges in Startups (00:25:38) Standardizing Agreements for Efficiency (00:33:42) Building Trust and Serving Academics (00:36:25) Academics' Service Level and Politics (00:37:47) The Ugly Side of Equity in Startups (00:48:32) European University Access vs. U.S. Student Debt (00:54:15) The Power of Alumni Networks and Global Impact (01:00:20) Leveraging Technology in Large Companies vs. Startups (01:08:22) The Ecosystem: Europe's Technological Landscape vs. the US (01:10:53) "Europe needs to beat the USA and China in technological advances." (01:12:02) The Dilemma of Localized Photonics Centers (01:18:13) The Global Mindset: From Europe to the U.S. and Beyond (01:24:02) Patent System's Evolution: From Mechanics to Modernity (01:31:10) AI in Business Planning: Efficiency vs. Insight (01:35:29) Optimizing Superconducting Material Combinations (01:40:44) Embracing AI: Beyond Fear and Biases (01:45:39) Technological Biases: Unintended Consequences of Regulation (01:54:08) The Dynamics of Billion-Dollar Valuations in Energy Sector (01:57:05) Embracing Humility: Knowing When to Seek Help (02:01:57) Science as Art: Celebrating Unsung Scientific Heroes
📣 Seeking tools to manage the entrepreneurial chaos? Dive into the world of innovation with Ash Ravikumar and discover how to optimize your processes for success.
MM 16: 🔥 Philipp Baaske: Unlocking the Cure: The Race Against Time in Cancer Research
00:10:00
Every year, 18 million souls are diagnosed with cancer - that's akin to the entire population of the Netherlands. But what if there was a way to release a cancer medication just a month earlier? Imagine the countless lives saved. Dive into this riveting conversation with Philipp Baaske, the visionary behind NanoTemper, as he unveils the power of perseverance, innovation, and the audacious ambition to treat every ailment known to humanity.
1️⃣ The Stark Reality: Grasp the magnitude of the global cancer crisis and the urgency of finding a cure.
2️⃣ What Awaits Inside:
Journey with Philipp Baaske from NanoTemper's humble beginnings to its groundbreaking contributions in biotech.
Discover the transformative tools reshaping drug discovery and their potential in the fight against cancer.
3️⃣ About Philipp Baaske: Philipp Baaske, co-founder and CEO of NanoTemper, is on a mission to arm scientists with cutting-edge tools, accelerating medical marvels. His story is a beacon of hope, belief, and relentless pursuit of a world where every disease is treatable.
📢 Engage with Us: If this narrative resonates with you, please subscribe, like, comment, and share. Your support amplifies our voice, bringing more such enlightening tales to the forefront.
🎉 Dive In: Embark on this enlightening journey into the world of biotech innovation. Let's explore the stories of those shaping our tomorrow.
MM 17: Daniel Vitt: Munich's Biotech Surge: The Untold Story Behind Europe's Innovation Hub
00:15:33
Munich, Bavaria - a picturesque city known for its rich history and Oktoberfest. But did you know it's also the epicenter of Europe's biotech revolution? Dive into this captivating conversation with Dr. Daniel Vitt, the driving force behind Immunic Therapeutics, as he unravels the secrets of Munich's meteoric rise in the biotech realm.
1️⃣ Munich's Meteoric Rise: Discover how Munich transformed into one of Europe's most dynamic biotech ecosystems, and the role of visionary political decisions in its ascent.
2️⃣ Inside Immunic's Journey: From its inception to its transformative stages, journey with Dr. Vitt as he shares the challenges and triumphs of leading a biotech giant. Learn about Immunic's groundbreaking developments and its innovative approach to treating diseases like multiple sclerosis.
3️⃣ About Dr. Daniel Vitt: Dr. Daniel Vitt, CEO of Immunic Therapeutics, is a biotech luminary with a rich legacy, including co-founding 4SC AG. His insights offer a rare glimpse into the intricacies of the global biotech landscape, from Europe to the US.
📢 Engage with Us: If this narrative resonates with you, please subscribe, like, comment, and share. Your support amplifies our voice, bringing more such enlightening tales to the forefront.
🎉 Dive In: Embark on this enlightening journey into the world of biotech innovation. Let's explore the stories of those shaping our tomorrow.
SP 14: Defying the Odds: Zuckerberg's Blueprint for Startup Resilience and Growth
00:19:00
Navigating the startup landscape is fraught with challenges that can make or break the boldest of visions. In this entrepreneurial climate, it's the audacious, the resilient, who rise to the top. Dive into this exclusive clip to discover the strategies that made Facebook a global phenomenon.
In a rare and revealing conversation, Mark Zuckerberg, the visionary founder and CEO behind Facebook, talks with Sam Altman, the respected president of Y Combinator and co-chairman of OpenAI, about the pivotal moments and decisions that shaped Facebook's destiny. From its inception in a college dorm to becoming a tech titan, Zuckerberg's insights are a treasure trove for aspiring entrepreneurs.
By watching, you'll delve into (01:41) Early Days of Facebook - Explore Zuckerberg's initial foray into what would become a global phenomenon. (04:03) Decision to Not Sell Facebook - Uncover the resolve behind rejecting a billion-dollar buyout. (07:07) Advice for Building Products - Gain foundational tips from a tech titan on product development. (10:48) Learning and Innovation Culture at Facebook - Get an insider look at fostering creativity and progress. (13:21) Hiring Philosophy - Learn Zuckerberg's strategy for assembling a team that disrupts and innovates. (16:05) Risk-Taking and Decision Making - Understand the calculated risks and decisions that shape the future of tech.
This episode is a beacon for entrepreneurs searching for guidance and inspiration. For a deeper exploration into the strategies that craft empires and the minds that envision them, watch the full interview for a comprehensive dive into the world of high-impact entrepreneurship:
Step into the arena armed with knowledge and ready to make your mark.
If the insights shared here strike a chord with you, take a moment to subscribe, like, comment, and share. Each interaction from you helps to elevate our conversation, bringing more profound insights and inspiring stories like this to light.
#119: Kara Moore - Innovating the Future: New Jersey's Bold Leap with NJEDA
01:12:00
Did you know that New Jersey is rapidly emerging as a powerhouse of innovation, especially in the life sciences and technology sectors?
Join us in this enlightening episode with Kara Moore from the New Jersey Economic Development Authority (NJEDA), as she unveils the state's strategic initiatives and opportunities for businesses and investors.
🎙️ What's in the Episode: 1️⃣ Financial Incentives for Growth: Kara discusses New Jersey's unique financial advantages for businesses, including converting net operating losses into non-dilutive capital. 2️⃣ Biomanufacturing and Industry Trends: Learn about New Jersey's focus on staying ahead in biomanufacturing through state-of-the-art facilities and training programs. 3️⃣ Helix Innovation Hub: Discover the significant investment in the Helix Innovation Hub, aimed at propelling health and life sciences R&D. 4️⃣ Diverse Talent Pool: Explore why New Jersey's dense and diverse population makes it an ideal location for companies seeking skilled talent. 5️⃣ Sci Tech City and Digital Health: Uncover the role of Sci Tech City in advancing digital health and A.I., marking New Jersey as a hub for technological growth.
👩💼 About Kara Moore: Kara Moore is a visionary leader at NJEDA, driving New Jersey's growth and positioning it as a key player in the global innovation market. Her focus on collaboration, innovation, and sustainable growth is shaping the state's future in business and technology.
📌 Quotes: (00:16:33) "It's like having free money. Our unique program allows companies to sell off their New Jersey net operating losses for non-dilutive capital." (00:25:17) "We're keeping on top of trends, developing programs like our biomanufacturing Pathways, and building facilities like the first simulated clean room in the state." (00:33:57) "We're building an Innovation Hub in New Brunswick, New Jersey – a $731 million investment in health and life sciences, dubbed Helix." (00:50:44) "We have about 445,000 life science workers in New Jersey. We're the most densely populated and fourth most diverse state in the country." (01:03:19) "Sci Tech City in Jersey City, just outside New York, will feature an eight-story incubation center focused on digital health and A.I. innovations." (01:04:33) "We partner with Hacks, a hard tech accelerator focusing on climate tech, offering significant funding and support for innovative companies in New Jersey."
⏰ Timestamps: (00:03:43) The Journey from Academia to Economic Development (00:07:43) How AI Transforms PR Work (00:09:43) Pioneering Life Sciences Growth in New Jersey (00:16:58) Transforming Tax Credits into Capital: How Companies Benefit (00:25:17) Bridging Trends and Training: New Jersey's Strategic Approach in Life Sciences (00:30:43) Shaping the Future Workforce: Collaborative Training in Biomanufacturing (00:33:57) Helix: A $731 Million Leap in Health and Life Sciences Innovation (00:44:18) Empowering Investors: New Jersey's Angel Tax Credit Program (00:50:44) New Jersey's Talent Magnet: Attracting Life Science Workers (00:56:52) Bridging Cultures: The Impact of Workforce Exchange Between Europe and the U.S. (01:02:14) Envisioning the Future: Life Science Innovations and Developments in New Jersey (01:04:02) Building the Hospital of the
EP 120: Matias Serebrinsky: Shaping the Future of Mental Health: AI, Psychedelics, and Beyond
01:29:03
Did you know that the intersection of mental health and cutting-edge technology is paving the way for revolutionary therapies that could redefine our approach to mental health and wellness?
Imagine a future where AI and novel therapies like psychedelics work together to unlock new realms of mental health treatment. Matias Serebrinsky and Psymed Ventures are at the forefront of this innovation, not just envisioning it—they're actively shaping it.
Tune in to explore the new horizons of mental health!
🎙️ What's in the Episode: 1️⃣ Mental Health Reimagined: He discusses the urgent need for innovative solutions in a world where mental health issues are a growing concern. 2️⃣ The Investment in Innovation: Discover how Psymed Ventures is not just a fund—it's a visionary platform that brings together groundbreaking research and entrepreneurial spirit to transform mental health care. 3️⃣ The Revolutionary Potential of Psychedelics: He shares insights into the promising future of psychedelic therapy, AI's role in personalized care, and how these could drastically improve outcomes for patients worldwide.
👨💼 About Matias Serebrinsky: He isn't just an investor; he's a catalyst for change. A passion has marked his journey from Argentina to Silicon Valley for disruptive technologies. As the force behind Psymed Ventures, Matias leverages his expertise in AI and his entrepreneurial background to champion a new era of mental health treatments that prioritize healing and holistic care. His philosophy is simple yet profound: invest in solutions that heal the mind and uplift humanity.
🎥 Don't miss this compelling episode where we delve into the future of mental health. Tune in now to understand how to join this mental health revolution.
📌 Quotes: (00:06:29) I'm keeping my Nvidia shares because Jensen is a once-in-a-generation type of founder, and you never want to bet against someone like that. (00:20:10) Mental health disorders are rapidly becoming the largest burden of disease for society, more costly than cancer and cardiovascular disease. (00:52:51) Psychedelics like iboga are being explored for opioid use disorder, showing significant effectiveness in initial studies. (01:07:13) Psychedelics can alleviate the lack of therapy supply. Comparing 40 hours of psychedelic therapy to 150 hours of traditional therapy shows where the equation makes more sense. (01:18:34) Some universities have streamlined the process, incentivizing professors to out-license or spin-out companies.
⏰ Timestamps: (00:02:15) Insights on Nvidia and Investment Strategy (00:05:53) Visionary Leadership: Nvidia's Strategic Shift to AI (00:09:00) Matias’ Journey from Argentina to Psymed Ventures (00:17:32) Veritas Health: A $2 Billion Success in Metabolic Dysfunction Treatment (00:19:37) Reducing Mental Health Stigma and Addressing Growing Needs in Society (00:33:56) Exploring Innovative Business Models in Mental Health Investment (00:41:43) Interventional Psychiatry: Revolutionizing Mental Health Treatment with Psychedelics (00:48:41) The Therapeutic Mystery of Psychedelics in Mental Health (00:52:51) Exploring Psychedelics for Addiction Treatment: Beyond Traditional Methods (01:06:41) Psychedelic Therapy: A New Paradigm in Mental Health (01:15:24) Innovating Mental Health Treatment: Neurostimulation at Home (01:17:
MM 18: Revolutionizing Mental Health: The Promise of Psychedelic Therapy with Matias Serebrinsky
00:06:48
Dive into a groundbreaking discussion with Matias Serebrinsky from Psymed Ventures, as we uncover the astonishing potential of psychedelic therapy in mental health. In this exclusive clip, Matias reveals groundbreaking clinical trial results for MDMA in treating PTSD, showing unprecedented remission rates and long-term healing. He also discusses the shift from traditional symptom management to actual healing, marking a paradigm shift in psychiatric treatment.
Discover how these therapies are not only changing lives but also reshaping our approach to mental health care. Don't miss Matias's insights into this revolutionary field. Watch the full episode for more in-depth analysis and discussions on the future of mental health treatments.
MM 19: Merry Christmas from Christian Soschner: Uniting Deep Tech with Timeless Wisdom
00:05:34
📢 About This Memorable Moment This festive season, I reflect on the journey we've shared through the 'Beginner’s Mind' podcast and our collective mission in the deep tech world.
📘 Inspiration Behind the Message: Drawing from the insights in Sebastian Mallaby’s 'The Power Law', I discuss how we’ve aimed to nurture connections within the deep tech ecosystem. My message intertwines the philosophies of my Christian and Buddhist heritage, emphasizing the importance of kindness and mutual respect.
🥋 Philosophy and Martial Arts: Explore how teachings from Jesus Christ, Viktor Frankl, and the principles of martial arts like Bujinkan have influenced my approach to life and business. These philosophies guide us to not take things personally, to ask questions, and to separate people from problems.
📊 Applying Philosophies to Business: Discover five simple yet impactful actions that can elevate startups, scale-ups, and public companies. These include active listening, understanding perspectives, creating win-win negotiations, and more.
🙏 A Universal Message: As we celebrate this festive season, let's embrace the spirit of the Golden Rule - a philosophy of kindness and mutual respect that transcends cultures and beliefs.
📌 Join the Conversation: I invite you to watch, reflect, and share your thoughts on how these philosophies resonate with you in your personal and professional life.
EP 121 - Matías Peire: How Can Latin America Revolutionize Global Biotech?
01:46:36
In this episode, we dive into a groundbreaking conversation with Matías Peire, a trailblazer in the biotech venture capital space. Discover how his innovative approach at GRIDX is reshaping the future of biotech in Latin America.
🎙️ What's in the Episode: 1️⃣ Bridging Science and Business: Matías discusses the unique challenges and opportunities in connecting Latin American scientific talent with global markets. 2️⃣ The GRIDX Approach: Discover how GRIDX is pioneering a new model for venture capitalism in biotech, focusing on nurturing startups right from the idea stage. 3️⃣ Latin America's Untapped Potential: Insights into the rich biodiversity and scientific talent in Latin America and how they can revolutionize biotech globally.
👨💼 About Matías Peire: Matías Peire, a visionary in the venture capital world, has a unique approach to investing in biotech startups. With a background in business administration and finance, and a deep passion for technology and science, Matías is leading GRIDX to transform scientific ideas into successful, impactful businesses. His journey is a testament to the power of visionary leadership in the biotech sector.
🎥 Don't miss this insightful episode where we delve into the world of biotech venture capitalism with Matías Peire. Tune in now to discover the future of biotech innovation in Latin America.
📌 Quotes: (00:06:32) "We want to transform how scientists create companies in Latin America." (00:34:35) "Scientists should become entrepreneurs and own their companies, licensing technology from universities." (00:48:07) "The only reason to become an entrepreneur is if you feel you'll regret not doing it." (00:57:50) "It's your responsibility to find a way to bring scientific alternatives to the table." (01:13:32) "You have a huge pool of talent, and almost none are working in the private sector." (01:32:43) "You need flexibility, ambition, and a soul in the game to succeed." (01:37:23) "Ambition to transform science into impact in Latin America."
⏰ Timestamps: 00:03:55) Climate Change and Venture Capital: Insights from Washington D.C. (00:05:43) Expanding Horizons: GRIDX's Growth Strategy in Latin America (00:18:03) Creating a Venture Capital Fund with a Company Builder Model in LATAM (00:26:49) Building Confidence in Latin American Science for Global Competitiveness (00:35:46) Bridging the Gap: Scientists and the Private Sector in LATAM (00:42:05) Professionalizing University Participation in Venture Capital Processes (00:51:54) Navigating the Storm: Impact as a Connector in Business and Science (00:58:50) The Responsibility of Transforming Production with Science (01:07:57) Achieving Success in Latin America: The Journey of Raising Funds Abroad (01:14:32) Leveraging Latin America's Talent Pool and Biodiversity for Global Impact (01:20:49) Latin American Projects: Showcasing Competitive Science on the Global Stage (01:33:03) Essential Qualities for Success: Learners, Builders, and Ambitious Minds (00:37:00) Keep pushing, it's going to be okay. Follow what you feel and keep pushing. (01:37:23) Ambition to transform science into impact in Latin America.
SP 15: 2024 Vision: Amplifying Deep Tech Voices – Insights from Investors and Entrepreneurs on 'Beginner's Mind'
00:05:03
Dive into the future with 'Beginner’s Mind' as I unveil the 2024 vision, a groundbreaking journey through the world of deep tech. In this special episode, join me for a riveting exploration into the minds of tech giants like Jeff Bezos, Warren Buffett, and Elon Musk. Discover exclusive insights that are shaping the future of technology and investment.
We're not just talking about trends; we're discussing real impact and growth. As we expand and professionalize our content, each conversation becomes a beacon for entrepreneurs and investors seeking a deeper understanding of the evolving digital landscape. From invaluable book reviews to compelling dialogues with leading figures, this episode is a treasure trove of wisdom for our ambitious audience.
Expect more than just interviews - get ready for a series of engaging, SEO-optimized discussions that not only resonate with your aspirations but also provide practical insights for your professional journey. Be part of a thought-provoking experience that connects you with the heart of innovation and investment in 2024.
Don't forget to support us with a like, comment, or a 5-star review on Apple Podcasts and Spotify, and subscribe on YouTube. Your engagement is our driving force in bringing more impactful content to the forefront of the deep tech world. Tune in to 'Beginner’s Mind' and transform the way you perceive the future of technology and business.
EP 122: Change-Makers of 2023: Discovering New Paths in Health, Technology, and Climate
00:36:40
Ready to make 2024 your best year ever?
If so, this episode is tailor-made for you. We've hand-picked the five most impactful, insightful, and exhilarating pieces of advice from various episodes of 2023, each poised to help you navigate the coming year with greater clarity and confidence.
First and foremost, a heartfelt thank you to every speaker who graced my show. Each conversation was a journey, each insight a treasure.
As I set out to select the five most inspiring, impactful, and insightful clips from different episodes for this special 'Best of 2023' compilation, I realized how every moment was invaluable.
Grateful for every guest, I turned to ChatGPT to impartially choose five episodes that offer guidance, wisdom, and foresight to navigate 2024 with clarity and purpose.
🔥 Are you ready to embrace 2024 with the wisdom of the past year? Dive into this meticulously curated episode that brings together the brilliance of thought leaders from diverse fields. This isn't just another podcast episode; it's a guidebook for your journey through 2024 and beyond.
In this episode, discover:
The transformative tale of a biotech entrepreneur's Christmas Eve breakthrough.
Insightful perspectives on the evolving landscape of mental health.
Innovative economic strategies transforming New Jersey's growth.
Urgent messages from the frontlines of climate change.
The promising potential of climate tech in creating a greener future.
Each segment is more than just a story; it's a beacon of knowledge and inspiration to guide you through the year. And to enrich your experience, we've included timestamps for each featured clip, allowing you to delve into the sections that resonate most with you. ⏰ Timestamps: (02:50) "The Christmas Eve Breakthrough: Nanotemper's Leap to Success" – Discover how a single crucial experiment on Christmas Eve catalyzed a biotech startup's journey to triumph. (09:26) "Redefining Mental Health: A New Era with AI and Psychedelics" – Explore Matias Serebrinsky's vision of the future of mental health treatment. (18:02) "New Jersey's Economic Revolution: Transforming Challenges into Opportunities" – Unveil Kara Moore's insights on New Jersey's innovative strategies for economic growth. (24:04) "Climate Urgency: A Scientist's Warning from Everest to NASA" – Delve into Dr. Kimberley R. Miner's compelling narrative on the immediate threats of climate change. (30:11) "Green Gold Rush: Yair Reem's Vision for Climate Tech" – Learn about the massive potential in climate technology with Yair Reem's forward-thinking approach. Join us on this enlightening journey as we explore, learn, and grow together. If this episode sparks curiosity, resonates with you, or inspires change, please like, comment, and share. Your engagement helps us continue bringing transformative conversations to light.
👉 Follow us for more insightful episodes: https://youtube.com/playlist?list=PLlZfrwd6iXrQWqnPV5UfnEMXeoX3wkycm&si=6BEIBb4gZIqcwknf
Remember, while this podcast is a treasure trove of knowledge, it is not a substitute for professional advice
EP 123 - Navigating the New Era of European Innovation with David Dana
01:53:30
🚀 Europe's Tech Transformation: David Dana's Vision for the Future!
In this episode, join me, Christian Soschner, for an enlightening conversation with David Dana, a leading figure in the European tech investment landscape. Discover how his strategic approach at the European Investment Fund (EIF) is driving innovation and shaping the future of technology in Europe.
🎙️ What's in the Episode: 1️⃣ Europe's Growing Tech Influence: David Dana discusses Europe's evolving role in the global tech market and its potential to become a key player. 2️⃣ The Art of Risk and Reward: Explore how embracing risk is essential for significant returns in the European investment scene. 3️⃣ Quantum Tech Revolution: Insights into the burgeoning field of quantum technologies and its global impact. 4️⃣ Collaborative Tech Transfer: Understanding the importance of openness in tech transfer to enhance ecosystem value. 5️⃣ Beyond Investing: Learn about EIF's strategic approach to deploying capital for broader market growth.
👨💼 About David Dana: David Dana, Head of VC Investments at EIF, is a mastermind in disruptive tech and innovation. With over a decade of experience at EIF and a profound understanding of various tech sectors, David is at the forefront of supporting Europe's tech sovereignty. His expertise in AI, Blockchain, Space, and Quantum Technologies, among others, is driving Europe's tech revolution.
🎥 Don't miss this insightful episode where we delve into the strategies and visions shaping Europe's tech future with David Dana. Tune in now to uncover the transformative power of European innovation.
📌 Quotes: (00:06:42) "Europe has a role to play in the global market." (00:27:34) "If you don't take the risk, you will not get the rewards." (00:34:50) "Quantum technologies are at the beginning of something potentially huge." (00:46:25) "Opening to other shareholders helps to value and support the ecosystem more effectively." (01:04:16) "We need to generate returns; it's not just about deploying, it's about investing." (01:20:30) “Europe has the capacity, knowledge, and brains to innovate and change the world.” (01:27:51) "We need to empower others by trusting them, giving them autonomy and responsibility."
⏰ Timestamps: (00:03:00) Discovering the European Investment Fund: David Dana's Journey (00:06:10) The Evolution of the European Tech Market: Insights from David Dana (00:17:46) Navigating Risk in Alternative Investments: David Dana's Perspective (00:21:05) The Exit Market Challenge: Europe vs. US in Venture Capital (00:31:45) Cultural Shift for European Innovation: Breaking National Barriers (00:34:50) Quantum Technologies: The Potential for Revolutionary Impact (00:45:50) Early Stage Funding and Tech Transfer in Europe: Challenges and Opportunities (00:48:32) Balancing Global Expansion and European Growth: Strategies for Tech Companies (00:59:30) Convincing Success: The Key to Gaining EIF Support (01:06:11) Navigating the Investment Process: EIF's Rigorous Due Diligence Approach (01:12:50) EIF's Rigorous Investment Process: Ensuring Quality and Due Diligence (01:24:32) Evolving Role of EIF: Focusing on Specialized Strategies in Europe (01:25:31) Empowering Teams for Decision-Making (01:38:15) Navigating Investment Successes and Failures (01:40:17) Confronting the Future with a Brave Initiative (01:50:19) Fos
#124: From Zero to Billion: How Venture Capital Shapes Our World | 'The Power Law' Review
01:17:18
Venture capital is the lifeblood of innovation, transforming bold ideas into groundbreaking realities.
Yet, navigating this high-stakes world is fraught with challenges that only the daring overcome. "The Power Law" by Sebastian Mallaby reveals the untold stories of the mavericks who dared to invest in the improbable, shaping our world with technologies once deemed impossible.
Why This Summary is a Must-Watch:
Decipher the DNA of Venture Success: Understand the principles that have propelled companies like Apple, Google, and Facebook to astronomical heights.
Learn from the Masters: Insights from legendary investors and firms like Sequoia Capital and Andreessen Horowitz.
Navigate the Highs and Lows: Real-life tales of venture capital hits and misses, including the meteoric rise of unicorns and the cautionary tales of Theranos and WeWork.
The Architect Behind 'The Power Law': A look into Sebastian Mallaby's background and how his insights offer a unique perspective on the VC world. Decoding "The Power Law": Explore the main concepts that govern venture capital success and failure. Quick Guide: The 7 Key Takeaways from the book for those short on time. Chapter Summaries: A detailed walkthrough of each chapter, highlighting crucial lessons, from the origins of VC to the latest trends shaping the future of technology and investment. Personal Reflection: My personal journey through the lens of Venture Capital and how "The Power Law" has reshaped my understanding of what it takes to succeed.
Don't miss out on this essential guide that could very well dictate the success of your next big venture or investment. Click to watch the episode now and step into the world of Venture Capital as you've never seen it before.
⏰ Timestamps: (00:00) Opening words (02:00) Sebastian Mallaby’s background (05:00) Main Concepts in “The Power Law” (08:33) Too long did not listen: The 7 Key Takeaways from the book (14:30) Chapter: Introduction (18:55) Chapter 1: Arthur Rock and Liberation Capital (23:01) Chapter 2: Finance without Finance (26:05) Chapter 3: The Genentech story (30:00) Chapter 4: The Whispering of Apple (34:04) Chapter 5: Silicon Valley’s culture of open collaboration and mutual support – Metcalfe’s Law (37:36) Chapter 6: Chance favors only the prepared mind combined with character and discipline (40:45) Chapter 7: Softbank’s 100 Million for everybody (44:00) Chapter 8: How to Build a Startup in a Saturated Market (47:20) Chapter 9: How Y-Combinator Redefined Early-Stage Investing (51:00) Chapter 10: The Rise of the Chinese Dragon (54:10) Chapter 11: Redefining Global Communication (57:20) Chapter 12: The Principle of Incremental Margins in Growth Investing (01:01:34) Chapter 13: Community fostered by Sequoia Capital (01:04:50) Chapter 14: What would Success in Venture be Without Failures Like Theranos or Wework? (01:08:25) Chapter: Conclusion by Mallaby (01:11:30) My conclusion
EP125 - Dan Bowyer: Revolutionizing Ventures: Dan Bowyer's Blueprint for Disruptive Success
01:34:57
🚀 Revolutionizing the Game: Dan Bowyer's Vision for the Future of Venture Capital!
In this compelling episode, join us as we unravel the insights and strategies of Dan Bowyer, a pioneering force in the venture capital world with SuperSeed VC. Discover how his unique approach is not just reshaping, but revolutionizing how startups navigate the journey from conception to global impact.
🎙️ What's in the Episode: 1️⃣ Disrupting Traditional Enterprises: Dan shares his mission to challenge the status quo, focusing on startups that enhance productivity and efficiency. 2️⃣ The SuperSeed Approach: Learn about SuperSeed VC's innovative strategy in investing early in technical founders, transforming how the world works. 3️⃣ Building Impactful Businesses: Insights into how Dan Bowyer and SuperSeed VC are fostering companies that prioritize both profitability and positive societal impact.
👨💼 About Dan Bowyer: With over 20 years of entrepreneurial and investing experience, Dan Bowyer is a co-founder and partner at SuperSeed VC, focusing on B2B, European AI-first startups. His passion lies in aiding technical founders to navigate the early stages of their journey, ensuring they not only achieve financial success but also make a meaningful impact in their sectors and beyond. Dan's philosophy is centered around making money and doing good, setting a new standard in the venture capital ecosystem.
🎥 Tune in to this insightful episode to delve into the visionary world of venture capital with Dan Bowyer. Discover the future of startup success and innovation with SuperSeed VC.
📌 Quotes: (00:06:18) "My passion is reflecting to founders the realities of raising capital." (00:20:55) "I discovered a thousand ways not to build a lightbulb." (00:36:52) "I just want to mess with enterprise, to truly disrupt the productivity and efficiency." (01:02:49) "We care that it transforms sectors, not about the sector itself." (01:04:24) "We use client engagement as a diligence process to gauge market pull." (01:22:37) "Solve problems. If you're not solving problems every board meeting, it's wrong." (01:32:02) "Make money and do good. Whether you're a founder or investor, improve the world."
⏰ Timestamps: (00:03:00) The Genesis of a Venture Capitalist: Dan Bowyer's Diverse Path (00:10:31) Tech Transformation: From Pop Star to Tech Savant (00:18:57) The Paradox of Success and the Joy of Building (00:21:17) Navigating Failures: The Pathway to Innovation (00:27:16) Europe's Reluctance to Risk and Its Global Impact (00:32:56) Harnessing European Talent and Innovation for Global Leadership (00:40:01) Bridging the Gap: Venture Capital and Societal Change (00:46:24) Defining True Entrepreneurship: Disruption and Transformation (00:51:49) Transforming Enterprise: Beyond Destruction to Innovation (00:59:23) The Evolution of Industry Giants: A Look Ahead (01:04:24) Validating Market Pull Through Founder Diligence (01:09:55) Deep Tech: Defining the Future Beyond Traditional Business Models (01:14:11) Betting on World-Class Teams to Solve AI Challenges (01:22:37) The Core Role of a Board: Problem Solving for Growth
Dive into this transformative discussion on venture capital, innovation, and making a positive impact. Remember to like, comment, and share to help grow our show and bring more insightful content like this to our community.
EP 126: Owen Reynolds is Changing the Game: Risk, Returns, & the Future of Tech
01:33:29
🚀 Navigating the Future: Owen Reynolds' Blueprint for Venture Capital Success!
Join us in this riveting episode as we explore the visionary mind of Owen Reynolds, a leading figure at Teklas Ventures, renowned for his strategic foresight in the venture capital arena. Delve into how Owen's innovative approach is not just navigating, but pioneering new pathways for startups to scale from groundbreaking ideas to global phenomena.
🎙️ What's in the Episode: 1️⃣ The Hardware Revolution: Owen discusses the critical role of hardware in catapulting technological advancements beyond current limitations. 2️⃣ Sustainable Energy for an Addicted World: Insights into the quest for cleaner, more sustainable energy sources to fuel our future. 3️⃣ Europe's Hidden Gems: Unveiling the untapped potential within Europe's tech landscape and the unique opportunities it presents.
👨💼 About Owen Reynolds: With a profound background in venture capital and a keen eye on industrial and energy sectors, Owen Reynolds stands at the helm of Teklas Ventures, steering investments towards automation, robotics, and sustainable energy solutions. His passion for marrying innovation with sustainability drives his mission to foster startups that not only succeed financially but also contribute positively to society. Owen's philosophy revolves around embracing risk for monumental returns, setting a new benchmark in venture capital.
🎥 Immerse yourself in this enlightening episode to journey into the future of venture capital with Owen Reynolds. Discover the strategies shaping the next wave of startup success and innovation with Teklas Ventures.
📌 Quotes: (00:07:45) "If I could do this for the rest of my life, it would be incredible." (00:17:11) "I invest in people that scare me a little bit." (00:43:03) "We can't get big capital flows without doing above market returns." (00:52:06) "Expecting market returns demands a mature set of founders and asset managers." (01:10:03) "Creative destruction is part of a healthy ecosystem, revitalizing it for future cycles." (01:24:33) "Every investment opportunity has its own risks and return profile, requiring a calculated approach." ⏰ Timestamps: (00:07:45) The Genesis of a Venture Capitalist's Passion (00:11:50) Envisioning the Future of Startups (00:17:11) Owen Reynolds on Seeking Founders Who Challenge Him (00:25:15) Discussing Modern Portfolio Theory in Venture Capital (00:42:04) Measuring Success in Venture Investment: Returns, Impact, Technology (00:43:03) Prioritizing Returns in Venture Capital for Sustainable Impact (00:43:49) Navigating ESG: Beyond Compliance to Genuine Impact (00:50:24) Investing in Down Markets: Overcoming Fear with Strategic Capital Allocation (00:59:16) Navigating Investment Strategies (01:10:03) Creative Destruction in the Venture Ecosystem (01:13:27) Navigating Venture Capital in a Shifting Market: Strategies for the Future (01:22:21) Envisioning the Venture Landscape: A Mature, Grounded Future for Startups (01:24:33) "Every investment opportunity has its own risks and return profile, requiring a calculated approach." (01:25:45) Exploring the Limits of Software in Technological Advancements (01:27:57) Envisioning a Future Shaped by Diverse Energy Sources and Sustainable Innovation
MM20: Alarming Disparities Exposed: A VC's Take on Health Equity - Squire Servance, Syridex Bio
00:10:17
Witness the raw truth as Squire Servance, founder of Syridex Bio, a healthcare impact investor, sheds light on the glaring health disparities in the US.
In this exclusive clip (full episode coming this week!), Squire dives deep into the root causes – from social determinants to systemic issues – and why a concerted effort across sectors is crucial for achieving true health equity.
This conversation matters to investors and C-level executives seeking to understand the hidden market potential and the social responsibility of addressing these disparities. Stay tuned!
MM21: Mastering Venture Capital in a Volatile Market: Insights from a Life Science Investor
00:09:11
Venture capital funding is drying up, but is this a crisis or an opportunity? Squire Servance, founder of Syridex Bio,, explains the "denominator problem," why savvy investors are targeting overlooked assets, and how his fund addresses health disparities.
EP 128: Squire Servance - Beyond Profit: Venture Capital’s Key Role in Solving Health Disparities
01:53:05
🚀 Investing with Impact: Squire Servance on Health Equity & Venture Capital
Unlock the power of venture capital to address health disparities and drive positive social change. In this insightful episode, we speak with Squire Servance, founder of health equity fund Syridex Bio. Discover his unique approach to investing in companies tackling underserved health needs, proving that profitability and purpose can coexist.
🎙️ What's in the Episode: 1️⃣ Investing in Overlooked Markets: Learn how health disparities create massive untapped opportunities for innovation and investment. 2️⃣ The Power of Diversity: Squire Servance explains why investing in diverse founders and solutions yields better outcomes for both society and investors. 3️⃣ Data-Driven Impact: Discover how Servance evaluates companies to ensure they drive both health equity progress and financial returns.
👨💼 About Squire Servance: Squire Servance is a visionary VC on a mission to accelerate health equity while generating transformative returns. His commitment to investing in solutions for underserved populations offers a powerful blueprint for venture capital that creates a healthier, more equitable world.
🎥 Watch this episode to gain valuable insights into how venture capital can be a force for good. Squire Servance's perspective is essential for impact-driven investors and anyone interested in the intersection of health and innovation.
📌 Quotes: (00:08:10) "The love just kind of grew, grew from there." (00:39:02) "Accelerating health equity, while generating returns, transforms lives and society." (00:57:45) "You can do good and do well by directing capitalism towards health equity." (01:17:35) "We're leaving money on the table by not investing in diverse founders." (01:25:46) "Everyone has blind spots; that's why diverse teams perform better." (01:45:29) "There's no shortcut for success."
⏰ Timestamps: (00:00:00) Introduction (00:02:42) The Genesis of a Life Sciences Revolution (00:08:48) Blueprint to Venture Capital: Squire's Journey (00:15:11) Igniting Change: The Genesis of a Health Equity Fund Amidst COVID (00:27:09) Venture Capital's Role in Bridging Health Disparities: A New Focus (00:28:58) Market Volatility: A Contrarian VC's Perspective (00:33:52) Health Equity as a Massive Global Market (00:48:00) The Evolution of Biotech Funding: From Genentech to Today (00:54:45) Tackling Health Equity: The Need for Collective Action (00:56:48) Harnessing Capitalism for Health Equity (01:03:30) The Role of Social Media and AI in Advancing Biotech Ventures (01:10:18) The Digital Footprint: How Online Presence Shapes VC Decisions (01:16:26) The Underrepresentation Crisis in VC Funding (01:24:54) Investing with a Broader Vision: (01:29:32) Investing in Health Equity (01:42:18) Expanding the Scope of Health Equity Investment (01:44:54) Success is Not a Shortcut: The Power of Consistency
#129: Elon Musk Leadership Formula: Risk, Ambition, and the Cost of Success (Walter Isaacson Biography Review)
01:24:50
Ever wondered what drives Elon Musk, the world's most controversial innovator?
This biography summary by Walter Isaacson dives into the complex mind of the man behind rockets, EVs, and the Twitter takeover.
In my martial arts days, a coach taught me to study exceptional role models – a strategy akin to the famous Harvard Business Cases. Analyze success, discover core principles, then adapt them to your own unique path. After all, as Bruce Lee said, "Absorb what is useful, reject what is useless, and add what is essentially your own."
That's the lens I bring to biographies – extracting valuable lessons amidst the complexities of each individual story. This time, we're dissecting Elon Musk. Walter Isaacson's fascinating book reveals the controversial genius behind Tesla, SpaceX, and his Twitter takeover.
Ever wondered what drives the world's most disruptive innovator?
Discover the secrets of Musk's ambition, his unconventional leadership, and the price of disrupting the status quo.
Feeling hesitant to take bold steps? Learn how Musk's embrace of risk fuels his extraordinary achievements.
Confused by his leadership tactics? Understand Musk's controversial style and question if it's the only path to world-changing innovation.
Unsure how to navigate ambition vs. ethics? Reflect on Musk's legacy and grapple with the genius vs. villain debate.
Why Listen:
Get the inside scoop. Explore Musk's childhood, his relentless drive, and the controversies he sparks.
Question the nature of leadership. Discover if Musk's methods are the future of industry disruption.
Challenge your own worldview. Decide where you stand on Elon Musk – visionary, ruthless, or something far more complex.
Quotes:
"I need to shift my mindset away from being in crisis mode, which it has been for about fourteen years now" - Elon Musk
"Could he have been more chill and still be the one launching us toward Mars and an electric-vehicle future?" - Walter Isaacson
Timestamps: (00:00) Intro to Elon Musk (03:10) Who is Walter Isaacson? (05:02) TLDR: Overview Biography Elon Musk by Walter Isaacson (07:30) Method and Focus of this Episode: Entrepreneurship and Investing Lessons Learned (09:30) Part 1: Childhood in South Africa – (P1-40) (15:30) Part 2: Starting With Nothing, Building an Empire (p 41 – 60) (19:00) Part 3: Early Ventures, Hard Lessons (p 60-82) (25:45) Part 4: Reaching for the Stars – Disrupting the Space Industry (p 83 – 123) (32:16) Part 5: Disruption Meets Drive (p 124 – 174) (39:28) Part 6: On the Brink – Resilience in the Face of Failure (p 174 – 222) (47:11) Part 7: The Musk Algorithm: Disruptive Leadership at Breakneck Speed (p 223 – 324) (56:00) Part 8: The Paradox of Musk: Visionary Drive vs. Personal Toll (p. 325 – 427) (01:02:00) Part 9: The Twitter Takeover: Transformative Disruption or Chaotic Destruction? (p 428 – 522) (01:11:00) Part 10: The Cost of Disruption: Leadership, Values, and the Future of Twitter ( p. 522 – 617) (01:18:20) 7 Key Takeaways (01:22:00) My Personal Reflection (01:23:00) Closing Remarks
Ep 130: Is Venture Debt the Missing Piece in Your Startup's Funding Puzzle? (EIB's Expert Reveals All)
00:33:06
What if there was a funding source that could supercharge your startup's growth without diluting your equity? It's not a pipe dream. It's venture debt – a powerful tool that many founders and investors haven't fully explored.
In this episode, we channel the spirit of learning from industry leaders, just as in the famous Harvard Business Cases. We dissect innovative financing strategies, focusing on venture debt – a secret weapon for companies looking to scale without sacrificing ownership.
We're joined by Gergely Krajcsi, a Senior Investment Officer at the European Investment Bank (EIB), Europe's leading provider of venture debt. This conversation happened at Bio Europe in Barcelona as a Fireside Chat on stage.
He'll reveal:
The hidden benefits of venture debt that 90% of startups are missing
How EIB's tailored solutions can supercharge your company's trajectory
Real-world success stories of European innovators fueled by venture debt
If you're a CEO or investor seeking a competitive edge, this episode is your blueprint. Uncover the funding strategy that could be the key to your next breakthrough.
Problems This Solves:
Funding Gap: Learn how to bridge the gap between venture capital rounds and unlock the capital you need to scale.
Equity Dilution: Discover how to fuel growth without sacrificing ownership in your company.
Limited Knowledge: Gain insider knowledge from the EIB's expert on the untapped potential of venture debt.
Why Watch:
Expert Insights: Get actionable advice directly from a leading venture debt provider.
Success Stories: See how other startups have used venture debt to achieve remarkable results.
Strategic Advantage: Gain a competitive edge by understanding this underutilized financing tool.
Key Quotes:
"Venture debt is a game-changer for startups looking to accelerate growth." - Gergely Krajcsi
"The EIB is committed to supporting European innovation through tailored financing solutions." - Gergely Krajcsi
Améliorez votre compréhension de Beginner's Mind avec My Podcast Data
Chez My Podcast Data, nous nous efforçons de fournir des analyses approfondies et basées sur des données tangibles. Que vous soyez auditeur passionné, créateur de podcast ou un annonceur, les statistiques et analyses détaillées que nous proposons peuvent vous aider à mieux comprendre les performances et les tendances de Beginner's Mind. De la fréquence des épisodes aux liens partagés en passant par la santé des flux RSS, notre objectif est de vous fournir les connaissances dont vous avez besoin pour vous tenir à jour. Explorez plus d'émissions et découvrez les données qui font avancer l'industrie du podcast.
